

TAIWAN

LIVE COURSE



TRANSCATHETER
THERAPEUTICS



2023 ———
01.07-08

社團法人臺灣介入性心臟血管醫學會
Taiwan Society of Cardiovascular Interventions

Keynote Speech Jan/8

Ultra-thin coronary stent struts
in multivessel disease

Dr. Patrick Serruys

Best-in-Class Ultra-Thin
60µm Coronary Stent
Now Available in Taiwan!

Supraflex
Cruz
Siralimus Eluting Cobalt Chromium Coronary Stent System

CE
2460

PUBLISHED IN

THE LANCET

FEBRUARY 28, 2019

3 Years Result Talent Trial 1435 patients

Supraflex SES* N=720



Xience EES** N=715

Difference %

97.8%
Follow-up @ 3 years

Intention-to-treat analysis¹

98.9%
Follow-up @ 3 years

8.1

DOCE (%)
Log-Rank p=0.406

9.4

-13.8

1.8

Cardiac Death (%)

2.1

-14.3

3.3

TV-MI (%)

4.6

-28.3

5.0

CI-TLR (%)

5.9

-15.3

1.1

Definite or Probable ST (%)

1.4

-21.4

Ultra-Thin

60 um all size 8mm~48mm

Easy to Push

mean push force only 0.10N

High Strength

Radio Strength 1093 mmHg,
Dislodgement force >5N

Rich Clinical Evidences

Talent published by Lancet/Euro Intervention,
RCT trials ongoing 6900+ patients

Unique 3-layer biodegradable Polymers



KUANG TAI



SMT

Welcome Message



Dear distinguished guests and TSCI members,

On behalf of the Taiwan Society of Cardiovascular Intervention (TSCI), I would like to extend my warmest welcome to all of you to participate in the Taiwan Transcatheter Therapeutics (TTT) 2023. Over the years, TTT provides a yearly platform to connect us with the world and excellent learning opportunities to achieve the purpose of inheritance.

After two years of Covid-19 ravage, this pandemic is finally reaching the end of its full impact on our life and daily activities. While we are picking up normal life and academic activities, I am delighted to announce that TTT 2023 is bracing for more enriched programs and more participants. This year, both APSIC and ENCORE SEOUL become our new partners in the international society session, and we are expecting our friends and experts from Hong Kong, Japan, and US to join us in person and have more face-to-face interactions. For those renowned experts who can't make it here this year, on-line participations is set up for them to engage in our live demo and other sessions.

As in the past, TTT2023 features one and a half days live demos on well-selected and educative cases to showcase the cutting edge treatments of coronary, peripheral and structural diseases by invited domestic masters. Watching these thrilling live demos will inspire our thinking and advance our skills in our daily cath practices.

As always, the well-organized international society sessions are musts to see and not to miss by any means. The chairmen, panelists, and the contents of any one of these sessions (TCT, TCTAP, CVIT, CCT, ENCORE SEOUL, APSIC, Cross-Strait) are masters from different countries and super-selected hot topics for deep diving. Anyone who finishes these sessions will be advanced in not only up-to-date knowledge but also in niche skills in interventions. Therefore, all of you are encouraged to indulge in these activities and have conversations with these big sharks. For those of you who are interested in structural and peripheral interventions, these sessions are also full of new devices, novel treatments, and unbelievable cases.

In alignment with advances in CHIP, our TTT 2023 also features lectures and learning center for the long-awaited Impella mechanical support device and a luncheon symposium dedicated to Intravascular Lithotripsy by Shockwave.

Last, but not the least, are the case competition sessions. These are always the foci of young interventionalists and showcase fabulous cases accomplished by marvelous intervention skills. All the attendants will be amazed by the most outstanding cases and inspired to do even more miraculous cases in their future interventional careers.

I am expecting to see all of you who can make it in person and those experts who can't make it this year on the line.

With all the above, TTT will flourish, strive for excellence, and make progress over the years.

Special thanks to

Tse-Min Lu, Chairman of Scientific Committee

Ta-Chuan Hung, Chairman of Education Committee


Hsien-Li Kao, Chairman of International and Cross Strait Committee

Yun-Ching Fu, Chairman of Structural Heart Diseases Committee

Cheng-Han Li, Chairman of Peripheral Vascular Interventions Committee

Yi-Kain Kuo, Chairman of Technical Staff Committee

Chi-Hung Huang, Secretary General



Wen-Lieng Lee, MD, PhD

Professor of Medicine

Course Director, TTT 2023

President, TSCI




Table of Contents

WELCOME MESSAGE	01
Table of Contents	04
Organizing Committee	06
Faculty	07
<ul style="list-style-type: none"> • International Faculty • Domestic Faculty 	
Venue	14
Floor Plan	15
Program at-a-glance	18
Program	21
Saturday & Sunday, January 7 – 8, 2023	22
<ul style="list-style-type: none"> • Live Demo 	
Saturday, January 7, 2023	30
AM	
<ul style="list-style-type: none"> • TCT@TTT Highlights (I) • TCTAP@TTT • CCT@TTT • Case Competition (I) • Luncheon Symposium (Abbott) • Luncheon Symposium (Biosensors) • Luncheon Symposium (Daiichi Sankyo) 	
PM	
<ul style="list-style-type: none"> • Cross-Strait Symposium • CVIT@TTT • Structural Symposium-Transcatheter mitral valve replacement • Evening Symposium (Bayer) • Evening Symposium (Novartis) • Evening Symposium (Shockwave Medical) 	

Sunday, January 8, 2023

48

AM

- Keynote Speech(II)
- ENCORE SEOUL@TTT
- APSIC@TTT
- Case Competition (II)
- Luncheon Symposium (AstraZeneca)
- Luncheon Symposium (Pfizer)
- Luncheon Symposium (Biotronik)

PM

- Keynote Speech (I)
- TCT@TTT Highlights (II)
- Peripheral Interventions
- Nurse/Tech Symposium

Learning Center

63

- R202 Medtronic
- R203 Abbott
- R205 Boston Scientific
- R402 Friends Biotec.

Live Transmission Cases

69

Acknowledgement 誠摯感謝

92

TTT 2023

COURSE DIRECTORS

Wen-Liang Lee, MD | 李文領醫師

President,

Taiwan Society of Cardiovascular Interventions

Taichung Veterans General Hospital, Taiwan

Tse-Min Lu, MD | 盧澤民醫師

Chairman of Scientific Committee,

Taiwan Society of Cardiovascular Interventions

Taipei Veterans General Hospital, Taiwan

Chi-Hung Huang, MD | 黃啓宏醫師

Secretary General,

Taiwan Society of Cardiovascular Interventions

Cathay General Hospital, Taiwan

SCIENTIFIC COMMITTEE

Ashok Seth, MD

Fortis Escorts Heart Institute, India

Gary S. Mintz, MD

Cardiovascular Research Foundation, USA

Ken Kozuma, MD

Division of Cardiology, Department of Internal
Medicine, Teikyo University School of Medicine,
Japan

Myeong-Ki Hong, MD

Severance Hospital, Yonsei University College of
Medicine, Korea

Seung-Jung Park, MD

Asan Medical Center, Korea

Takafumi Tsuji, MD

Kusatsu Heart Center, Japan

ON SITE DIRECTORS

Tse-Min Lu, MD | 盧澤民醫師

Taipei Veterans General Hospital, Taiwan

Chi-Hung Huang, MD | 黃啓宏醫師

Cathay General Hospital, Taiwan

Cheng-I Cheng, MD | 鄭正一醫師

Kaohsiung Chang Gung Memorial Hospital, Taiwan

INTERNATIONAL FACULTY

* On Site International Faculty

Australia

***Bryan Ping-Yen Yan**

The Chinese University of Hong Kong

李長嶺 Chang-Ling Li

The Second Affiliated Hospital of Zhejiang
University School of Medicine

Bangladeshi

Fazila Malik

National Heart Foundation Hospital & Research
Institute

France

Honton Benjamin

Clinique Pasteur

British

Joel Giblett

Liverpool Heart and Chest Hospital

Germany

Eberhard Grube

University Hospital Bonn

Georg Nickenig

University Hospital Bonn

Canada

Gilbert Tang

Mount Sinai Health System

Ralph Stephan von Bardeleben

University Medical Center of Mainz, Heart
Valve Center

Michael Joner

German Heart Centre Munich

China

王焱 Yan Wang

Xiamen Cardiovascular Hospital

陳紹良 Shao-Liang Chen

Nanjing First Hospital

徐亞偉 Ya-Wei Xu

Shanghai Tenth People's Hospital

陳紀言 Ji-Yan Chen

Guangdong Provincial Hospital

陳良龍 Liang-Long Chen

Union Hospital, Fujian Medical University

唐熠達 Yi-Da Tang

Peking University Third Hospital

蘇晞 Xi Su

Wuhan Asia Heart Hospital

薛強 Qiang Xue

Yan'an Affiliated Hospital to Kunming Medical
University

Hong Kong

***Ho Lam**

Tuen Mun Hospital

***Frankie Tam**

Queen Mary Hospital

李耿淵 Michael Kang-Yin LEE

Queen Elizabeth Hospital

徐家龍 Ka-Lung Chui

Prince of Wales Hospital

India

Ashok Seth

Fortis Escorts Heart Institute

Rajinikanth Rajagopal

Gleneagles JPMC

INTERNATIONAL FACULTY

* On Site International Faculty

Indonesia

Teguh Santoso
Medistra Hospital

Ireland

Patrick Serruys
University of Galway

Italy

Antonio Mangieri
IRCCS Humanitas Research Hospital

Japan

***Masahiko Ochiai**
Showa University Northern Yokohama Hospital

Satoru Sumitsuji
Osaka University Graduate School of Medicine

***Sunao Nakamura**
New Tokyo Hospital

Kenya Nasu
Mie Heart Center

Yasumi Igarashi
Sapporo Kosei General Hospital

***Takafumi Tsuji**
Kusatsu Heart Center

Kentaro Hayashida
Keio University School of Medicine

Yuji Ikari
Tokai University

Osamu Iida
Kansai Rosai Hospital, Cardiovascular Center

Yoshimitsu Soga
Department of Cardiology, Kokura Memorial Hospital

*Ken Kozuma

Division of Cardiology, Department of Internal Medicine, Teikyo University School of Medicine

Maoto Habara

Toyohashi Heart Center

Katsuyuki Hasegawa

Higashi Takarazuka Satoh Hospital

Shunsuke Matsuno

The Cardiovascular Institute

Shinjo Sonoda

Department of Cardiovascular medicine, Saga University

Hitoshi Matsuo

Gifu Heart Center / Department of Cardiovascular Medicine

Takayuki Warisawa

NTT Medical Center Tokvo/St. Marianna University School of Medicine

Fumiyasu Seike

Ehime University

Yuhei Kobayashi

NY Presbyterian Brooklyn Methodist Hospital/ Weill Cornell Medical College

Toshiro Shinke

Showa University Hospital

Yoshinori Kanno

Tokyo Medical and Dental University, Cardiovascular Division

Taku Asano

Cardiovascular center, St. Luke's International Hospital

Takashi Kubo

Naga Minicipal Hospital

INTERNATIONAL FACULTY

* On Site International Faculty

Korea

Seung-Jung Park
Asan Medical Center

Hyo-Soo Kim
Seoul National University Hospital

***Myeong-Ki Hong**
Severance Hospital, Yonsei University College
of Medicine

Duk-Woo Park
Asan Medical Center

Jung-Min Ahn
Asan Medical Center, University of Ulsan

Do-Yoon Kang
Asan Medical Center

Young Won Yoon
Gangnam Severance Hospital, Yonsei
University College of Medicine

Choongki Kim
Ewha Womans University College of Medicine
Seoul Hospital

Joo-Yong Hahn
Samsung Medical Center, Sungkyunkwan
University School of Medicine

Kyung Woo Park
Seoul National University Hospital

Singapore

Huay-Cheem Tan
National University Heart Centre

Steven Kum
Mount Elizabeth Novena Hospital

Sweden

Elmir Omerovic
Sahlgrenska University Hospital

Switzerland

Fabien Praz
University Hospital Bern

UK

Ziad A Ali
St Francis Hospital, The Heart Center

Keith Oldroyd
Golden Jubilee National Hospital

USA

***Gary S. Mintz**
Cardiovascular Research Foundation

Emmanouil S. Brilakis
Minneapolis Heart Institute

Suzanne V. Arnold
Saint Luke's Mid America Heart Institute/
University of Missouri-Kansas City

Ajay J. Kirtane
Columbia University Medical Center

Scott Lim
University of Virginia

Luigi Pirelli
Lenox Hill Hospital at Northwell Health

Mohamad A. Alkhouli
Mayo Clinic

DOMESTIC FACULTY

于慶龍	Ching-Lung Yu	宋沛勳	Pei-Hsun Sung
方志元	Chih-Yuan Fang	宋思賢	Shih-Hsien Sung
方修御	Hsiu-Yu Fang	李永在	Yung-Tsai Lee
方慶章	Ching-Chang Fang	李任光	Jen-Kuang Lee
王子林	Tzu-Lin Wang	李庚原	Keng-Yuan Lee
王光德	Kuang-Te Wang	李俊偉	Chun-Wei Lee
王宇澄	Yu-Chen Wang	李信賦	Hsin-Fu Lee
王志鴻	Ji-Hung Wang	李建和	Chien-Ho Lee
王奇彥	Chi-Yen Wang	李政翰	Cheng-Han Li
王宗道	Tzung-Dau Wang	李素珠	Su-Chu Lee
王怡智	Yi-Chih Wang	李貽恆	Yi-Heng Li
王鳳花	Feng-Hua Wong	李慶威	Ching-Wei Lee
王駿丞	Chun-Cheng Wang	李應湘	Ying-Hsiang Lee
任勗龍	Hsu-Lung Jen	周柏青	Po-Ching Chou
朱永謙	Yung-Hua Chu	周嘉裕	Chia-Yu Chou
朱俊源	Chun-Yuan Chu	林子翔	Tzu-Hsing Lin
江孟修	Meng-Hsiu Chiang	林志展	Chih-Chan Lin
何明昀	Ming-Yun Ho	林佳濱	Chia-Pin Lin
何智仰	Chia-Yang Ho	林宗憲	Tsung-Hsien Lin
吳卓鎔	Cho-Kai Wu	林宜慶	Yi-Ching Lin
吳承學	Cheng-Hsueh Wu	林岳鴻	Yueh-Hung Lin
吳炯仁	Chiung-Jen Wu	林俊呈	Jiunn-Cherng Lin
吳敘平	Hsu-Ping Wu	林俊彰	Jiunn-Wen Lin
吳莉娟	Li-Jiuan Wu	林彥宏	Yen-Hung Lin
吳道正	Tao-Cheng Wu	林柏霖	Po-Lin Lin
呂信邦	Hsin-Bang Leu	林茂欣	Mao-Shin Lin

DOMESTIC FACULTY

林莉萍	Li-Ping Lin	張嘉修	Chai-Hsiu Chang
林瓊枝	Chiung-Chih Lin	張韶政	Shavr-Zheng Chong
邱正安	Cheng-An Chiu	張興亞	Hsing-Ya Chang
邱昱偉	Yu-Wei Chiu	張獻元	HsienYuan Chang
邵雅芬	Ya-Fen Shao	曹承榮	Chen-Rong Tsao
施志遠	Jhieh-Yuan Shih	曹殿萍	Tien-Ping Tsao
施俊明	Chun-Ming Shih	梁凱偉	Kae-Woei Liang
柯文欽	Wen-Chin Ko	梁懷文	Huai-Wen Liang
柯毓麟	Yu-Lin Ko	許育誠	Yu-Cheng Hsu
洪大川	Ta-Chuan Hung	許栢超	Po-Chao Hsu
夏建勳	Chien-Hsun Hsia	許智能	Chih-Neng Hsu
徐千彞	Chien-Yi Hsu	許榮城	Jung-Cheng Hsu
徐中和	Chung-Ho Hsu	郭李堂	Li-Tang kuo
殷偉賢	Wei-Hsian Yin	郭宜蘭	Yi-Lain Kou
馬光遠	Guang-Yuan Mar	郭風裕	Feng-Yu Kuo
高瑜成	Yu-Cheng Kao	陳志成	Zhieh-Cherng Chen
高憲立	Hsien-Li Kao	陳良維	Liang-Wei Chen
常敏之	Min-Ji Chang	陳典佑	Tien-Yu Chen
張永明	Yung-Ming Chang	陳念中	Nien-Chung Chen
張其任	Chi-Jen Chang	陳怡芝	I-Chih Chen
張俊欽	Chun-Chin Chang	陳怡誠	I-Chen Chen
張恒嘉	Heng-Chia Chang	陳俊吉	Chun-Chi Chen
張劍監	Chao-Chien Chang	陳冠宇	Kuan-Yu Chen
張偉俊	Wei-Chun Chang	陳威達	Wei-Ta Chen
張雲德	Jun-Ted Chong	陳昱璋	Yu-Wei Chen
張詩聖	Shih-Sheng Chang	陳盈憲	Ying-Hsien Chen

DOMESTIC FACULTY

陳科維 Ke-Wei Chen

陳郁志 Michael Yu-Chih Chen

陳清埤 Ching-Pei Chen

陳逸忠 I-Chung Chen

陳隆景 Lung-Ching Chen

陳業鵬 Yeh-Peng Chen

陳鉞忠 Yueh-Chung Chen

陳橙葦 Cheng-Wei Chen

陳嬰華 Ying-Hwa Chen

傅雲慶 Yun-Ching Fu

曾春典 Chuen-Den Tseng

曾欽輝 Chin-Hui Tseng

曾維功 Wei-Kung Tseng

黃日新 Jih-Hsin Huang

黃少嵩 Shao-Sung Huang

黃世忠 Shih-Chung Huang

黃玄禮 Hsuan-Li Huang

黃成偉 Chen-Wei Huang

黃建銘 Chien-Ming Huang

黃建龍 Chien-Lung Huang

黃柏勳 Po-Hsun Huang

黃偉春 Wei-Chun Huang

黃瑞仁 Juey-Jen Hwang

黃群耀 Chun-Yao Huang

黃漢龍 Han-Lung Huang

黃銘玲 Ming-Ling Huang

黃爽毓 Shih-Yu Huang

黃慶昌 Ching-Chang Huang

楊淵博 Yuan-Po Yang

楊欽文 Chien-Boon Jong

楊登堯 Teng-Yao Yang

葉仲軒 Jong-Shiuan Yeh

葉志凡 Chih-Fan Yeh

葉漢根 Hon-Kan Yip

葉勳龍 Hsing-Long Yeh

詹世鴻 Shih-Hung Chan

詹貴川 Kuei-Chuan Chan

廖智冠 Chih-Kuan Liao

趙庭興 Ting-Hsing Chao

劉世奇 Shih-Chi Liu

劉如濟 Ju-Chi Liu

劉秉彥 Ping-Yen Liu

劉俊廷 Jun-Ting Liou

劉俊傑 Chun-Chieh Liu

劉尊睿 Tsun-Jui Liu

劉維新 Wei-Shin Liu

劉銘恩 Ming-En Liu

潘龍發 Lung-Fa Pan

蔡天堯 Tien-Yao Tsai

蔡佳靚 Chia-Ti Tsai

蔡其峰 Chi-Feng Tsai

蔡政廷 Cheng-Ting Tsai

DOMESTIC FACULTY

鄧欣一	Hsin-I Teng
鄭又誠	You-Cheng Zheng
鄭正一	Cheng-I Cheng
鄭正忠	Cheng-Chung Cheng
鄭成泉	Chen-Chuan Cheng
鄭書孟	Shu-Meng Cheng
鄭曉揚	Hsiao-Yang Cheng
鄭錦昌	Chin-Chang Cheng
盧怡旭	Ye-Hsu Lu
盧炯睿	Chiung-Ray Lu
盧澤民	Tse-Min Lu
賴志泓	Chih-Hung Lai
薛書凱	Shu-kai Hsueh
謝宜璋	I-Chang Hsieh
謝明哲	Ming-Jer Hsieh
謝敏雄	Ming-Hsiung Hsieh
謝慕揚	Mu-Yang Hsieh
鍾文榮	Wen-Jung Chung
鍾伯欣	Bor-Hsin Jong
鍾宏濤	Hung-Tao Chung
鍾政達	Cheng-Ta Chung
羅秉漢	Ping-Han Lo
蘇河名	Ho-Ming Su
蘇界守	Chieh-Shou Su
蘇峻弘	Chun-Hung Su
顧博明	Po-Ming Ku

GUIDE MAP




 **Sheraton** (喜來登)

NTUH International Convention Center (台大國際會議中心)

TAIWAN TRANSCATHETER THERAPEUTICS 2023 Floor Plan

Date January 7-8, 2023

Venue NTUH International Convention Center



2F

Luncheon Symposium (12:10~13:20)

1/7 (SAT) R201 Abbott
1/8 (SUN) R201 AstraZeneca

Evening Symposium (17:10~18:10)

1/7 (SAT) R201 Bayer

Learning Center

R202 Medtronic
R203 Abbott
R205 Boston Scientific


Booth

A-01 Boston Scientific	B-09 Asahi
A-02 Pfizer	B-10 AstraZeneca
A-03 Lorion	B-11 AstraZeneca
A-04 BIOTRONIK	C-12 Medtronic
A-05 Terumo	C-13 Medtronic
B-06 Sanofi	C-14 Abbott
B-07 Hsin Tung/Abiomed	C-15 Abbott
B-08 Kuangtai	

TAIWAN TRANSCATHETER THERAPEUTICS 2023 Floor Plan

Date January 7-8, 2023

Venue NTUH International Convention Center



3F

3F

Luncheon Symposium (12:10~13:20)

1/7 (SAT) R301 Biosensors
 1/8 (SUN) R301 Pfizer

Evening Symposium (17:10~18:10)

1/7 (SAT) R301 Novartis

Domestic Faculty Registration

國內貴賓報到處

Pre-Registration & On-Site Registration

一般參加者報到處


Booth

3A-01	Biosensors	3C-07	Daiichi Sankyo
3B-02	Biosensors	3C-08	Chung Tuo
3C-03	Wattcan	3C-09	MicroPort
3C-04	Wattcan	3C-10	Orient EuroPharma
3C-05	B.Braun	3C-11	Novartis
3C-06	B.Braun	3C-12	Novartis

TAIWAN TRANSCATHETER THERAPEUTICS 2023 Floor Plan

Date January 7-8, 2023

Venue NTUH International Convention Center



4F

4F

Luncheon Symposium (12:10~13:20)

1/7 (SAT) R401 Daiichi Sankyo
1/8 (SUN) R401 Biotronik

Evening Symposium (17:10~18:10)

1/7 (SAT) R401 Shockwave Medical

Learning Center

R402B Friends Biotec.

R403 Preview Room

R403 試片室

Booth

4A-01 WS Far IR Medical

4B-02 Eucatech

4B-03 COSMO MEDICAL

4B-04 Bayer

R405 Faculty Lounge

R405 Faculty Lounge

TRANSCATHETER THERAPEUTICS

2023 ———
01.07-08

NTUH International Convention Center



DAY 1	Venue	201(2F)	301(3F)	401(4F)	2F/4F	2-4F
	Time					
Jan.7 (Sat) AM	08:30 10:15	Live Demo	08:20-10:05 TCT@TTT Highlights (I)	Case Competition (I)	Learning Center	Exhibition
	10:15 12:00	Live Demo	10:05-11:05 TCTAP@TTT 11:05-12:05 CCT@TTT			
LUNCH TIME	12:10 13:20	Luncheon Symposium (Abbott)	Luncheon Symposium (Biosensors)	Luncheon Symposium (Daiichi Sankyo)	R202 R203 R205 R402B	
Jan.7 (Sat) PM	13:30 15:15	Live Demo	13:30-15:40 Cross-Strait Symposium	Structural Symposium		
	15:15 17:00	Live Demo	15:50-17:00 CVIT@TTT			
	17:10 18:10	Evening Symposium (Bayer)	Evening Symposium (Novartis)	Evening Symposium (Shockwave Medical)		

TAIWAN

LIVE COURSE

TRANSCATHETER THERAPEUTICS

2023
01.07-08

NTUH International Convention Center



DAY 2	Venue	201(2F)	301(3F)	401(4F)	2F/4F	2-4F
	Time					
Jan.8 (Sun) AM	08:10 08:30			General Assembly	Learning Center R202 R203 R205 R402B	Exhibition
	08:30 10:15	Live Demo	08:30-09:40 Keynote Speech (II)	Case Competition (II)		
	10:15 12:00	Live Demo	09:50-10:50 ENCORE SEOUL @TTT			
LUNCH TIME	12:10 13:20	Luncheon Symposium (AstraZeneca)	Luncheon Symposium (Pfizer)	Luncheon Symposium (Biotronik)		
	13:30 15:00	Keynote Speech (I)	13:30-15:30 Peripheral Symposium	13:30-15:40 Nurse/Tech Symposium		
Jan.8 (Sun) PM	15:00 17:00	TCT@TTT Highlights (II)				

Any where , Any reach

AnyreachP™ & AnyreachC™

PTCA Guidewire

- Core-to-Tip and Dual-Core Tip Design
- Support Shaft: Stainless Steel
- AnyreachP™ series: P for Polymer:
the smooth feel you wish for
- AnyreachC™ series: C for Coil:
the metal coil gives you real tactile feedback



- Tip load 0.3/0.6/1.0g



- Tip load 0.3/0.6/1.0g

CONQUEROR™ Trap

Trapping balloon catheter



Crossing Profile

0.026"/0.66mm/2F

Spiral Catheter Design

Descending stiffness
to balance pushability
and flexibility

Compatible Products						In Guiding Catheter
Double Lumen Microcatheter 3.2F ,Instantpass2.6/1.9/1.7F,Corsair 2.6F, Finecross 1.8F						6F
Stingray LP Catheter						6F
Crossboss CTO Catheter						7F
Ratablator 1.5mm						8F

Shaft O.D.	Crossing profile	Balloon Diameter	Balloon Length	Working Length	Number of Depth Marker(s)
1.3F	2.0F	2.5mm	12mm	112cm	2



APT Medical



法蘭德
FRANCE BIOTEC



TTT 2023 Program



Scan the QR Code for
the Updated Program
(最新課表)

Day 1 : Live Transmission I & Lecture

Saturday (W6), January 7, 2023 08:30-10:15

R 201

Live Site : Taipei Veterans General Hospital

Chairs :

Wen-Lieng Lee (李文領), Chiung-Jen Wu (吳炯仁), *Masahiko Ochiai,
 Michael Lee, Huay-Cheem Tan

Commentators :

*Ho Lam, Shao-Liang Chen (陳紹良), Liang-Long Che (陳良龍),
 Wei-Chun Huang (黃偉春), Jung-Cheng Hsu (許榮城), Ching-Pei Chen (陳清埤),
 Feng-Yu Kuo (郭風裕), Tsun-Jui Liu (劉尊睿), Shu-Meng Cheng (鄭書孟)

IVUS/OCT Commentators :

Hsin-I Teng (鄧欣一), Ching-Chang Huang (黃慶昌)

08:20-08:30

Opening Ceremony

Wen-Lieng Lee President, TSCI (李文領理事長)

Room 1 : CTO

Operator : Tse-Min Lu (盧澤民)

08:30-10:15

Room 2 : CHIP

Operator : Shao-Sung Huang (黃少嵩)

Room 3 : OCT guided ROTA

Operator : Chi-Jen Chang (張其任)

09:15-09:25

Lecture 1 : Recorded LIVE Cases for Use of Impella in Cardiogenic Shock

Speaker : Ho Lam

Day 1 : Transmission II & Lecture

Saturday (W6), January 7, 2023 10:15-12:00

R 201

Live Site : Taipei Veterans General Hospital

Chairs :

Juey-Jen Hwang (黃瑞仁), Hsuan-Li Huang (黃玄禮), Ta-Chuan Hung (洪大川),
Ashok Seth, *Sunao Nakamura

Commentators :

Yoshimitsu Soga, Yuji Ikari, Ya-Wei Xu (徐亞偉), Yi-Da Tang (唐熠達),
Po-Chao Hsu (許栢超), Hsu-Lung Jen (任勗龍), Michael Yu-Chih Chen (陳郁志),
Yu-Cheng Kao (高瑜成), Mu-Yang Hsieh (謝慕揚)

IVUS/OCT Commentators :

Hsin-I Teng (鄧欣一), Ching-Chang Huang (黃慶昌)

Room 1 : CTO

Operator : Cheng-Han Li (李政翰)

10:15-12:00

Room 2 : Peripheral

Operator : Cheng-Hsueh Wu (吳承學)

Room 3 : Peripheral

Operator : Jen-Kuang Lee (李任光)

11:00-11:10

Lecture 2: Dual Therapy EPC Capturing Sirolimus Eluting Combo Plus Stent

Speaker : Jung-Cheng Hsu (許榮城)

Day 1 : Live Transmission III & Lecture

Saturday (W6), January 7, 2023 13:30-15:15

R 201

Live Site : Cathay General Hospital

Chairs :

Wei-Hsian Yin (殷偉賢), Tien-Ping Tsao (曹殿萍), Eberhard Grube,
 Hyo-Soo Kim, *Takafumi Tsuji

Commentators :

Kentaro Hayashida, Ka-Lung Chui (徐家龍), Ying-Hwa Chen (陳嬰華),
 Chien-Ming Huang (黃建銘), Jun-Ting Liou (劉俊廷), Yu-Chen Wang (王宇澄),
 Cheng-Chung Cheng (鄭正忠), Ching-Chang Huang (黃慶昌), Jiunn-Cherng Lin (林俊呈)

IVUS/OCT Commentators :

Chih-Kuan Liao (廖智冠), Chia-Pin Lin (林佳濱)

Room 1 : CTO

Operator : Shih-Chi Liu (劉世奇)

13:30-15:15

Room 2 : Bifurcation Lesion

Operator : I-Chung Chen (陳逸忠)

Room 3 : TAVI

Operator : Chi-Hung Huang (黃啓宏) / Jung-Cheng Hsu (許榮城)

14:15-14:25

Lecture 3 : Optimizing Outcomes in Complex PCI with SYNERGY XD

Speaker : Tien-Ping Tsao (曹殿萍)

Day 1 : Live Transmission IV & Lecture

Saturday (W6), January 7, 2023 15:15-17:00

R 201

Live Site : Cathay General Hospital

Chairs :

Chia-Yu Chou (周嘉裕), Chi-Jen Chang (張其任), *Myeong-Ki Hong,
Georg Nickenig, Teguh Santoso

Commentators :

*Frankie Tam, Chun-Ming Shih (施俊明), Chun-Yao Huang (黃群耀),
Chih-Hung Lai (賴志泓), Jun-Ted Chong (張雲德), Cheng-I Cheng (鄭正一),
Po-Ming Ku (顧博明), Ping-Han Lo (羅秉漢), Shih-Hsien Sung (宋思賢), Wei-Ta Chen (陳威達)

IVUS/OCT Commentators :

Chih-Kuan Liao (廖智冠), Chia-Pin Lin (林佳濱)

Room 1 : CTO

Operator : Cheng-Ting Tsai (蔡政廷)

15:15-17:00

Room 2 : Calcification lesion

Operator : Ji-Hung Wang (王志鴻)

Room 3 : LAA

Operator : Shih-Yu Huang (黃爽毓)

16:00-16:10

**Lecture 4 : A Case Sharing of Simultaneous Transcatheter
Valve-in-Valve Implantation of MyVal in Degenerated Mitral and
Tricuspid Xenograft**

Speaker : Jih-Hsin Huang (黃日新)

SAVE MORE LIVES



BRILINTA CAN MAKE THE DIFFERENCE



急性冠心症

與Aspirin併用，與
Clopidogrel相比，Brilinta
可以降低心血管死亡、
心肌梗塞風險



心肌梗塞病史

與Aspirin併用，可減少有心
肌梗塞病史併伴有高風險
發生動脈血栓事件病人之
心血管死亡、心肌梗塞或
中風發生率



急性缺血性腦中風或 暫時性腦缺血 (TIA)

與Aspirin併用，用於降
低急性缺血性腦中風
(NIHSS 分數 ≤ 5) 或高風
險暫時性腦缺血病人之
中風風險。

百無凝膜衣錠60毫克，90毫克 BRILINTA™ (ticagrelor) Film-coated Tablets 60 mg, 90 mg

衛部醫字第021438號 衛署藥輸字第02999號

【適應症】急性缺血性腦中風或暫時性腦缺血 【用法用量】 Brilinta與Aspirin併用時，Aspirin之每日維持劑量不可超過100 mg。急性冠心症：Brilinta的預載劑量 (loading dose) 為單劑180 mg (兩顆90 mg錠劑)，接著每290 mg，每日兩次，連續治療持續12個月，除非臨床上有需要停藥。使用Brilinta加上Aspirin每日維持劑量75-100 mg。心肌梗塞病史：Brilinta 60 mg每日兩次連續在有一年以上LMI病史合併有高風險發生動脈血栓事件病人，需要延長治療時使用，高風險動脈血栓事件的ACS病人，使用Brilinta 90 mg或其他二磷酸腺苷 (ADP) 受體抑制劑療法初步一年治療之後，Brilinta 60 mg每日兩次可作為後續治療而無須中斷。治療亦可在發生MI後2年內，或停用先前ADP受體抑制劑治療後1年內開始。Brilinta作為延長治療超過3年的療效和安全性資料有限。急性缺血性腦中風或暫時性腦缺血 (TIA)：Brilinta與Aspirin併用治療：開始治療時，Brilinta的預載劑量為單次口服180 mg，後續則每兩次，每次口服90 mg，每次持續30天，療效在療效初期顯現。Aspirin的預載劑量為單次口服300至325 mg，後續則每日一次，每次口服75-100 mg。如果患者要更改藥物，第一劑Brilinta於最後一劑阿司匹林血小板藥物後24小時給予。如果病人錯過一劑Brilinta，應於下次服藥時間僅服用一劑錠劑 (即下一次劑量)。無法吞嚥錠劑之病人可將Brilinta錠劑壓碎後混入水中吞下。該混濁液亦可透過鼻胃管 (CH或更大) 給藥。【禁忌症】 腦內出血病史、活動性出血、過敏反應、重度肝功能不全。【警語和注意事項】 出血風險：抑制血小板功能的藥物會增加出血風險。Brilinta不可用於活動性病理生理性出血或腦內出血病史者。急性缺血性腦中風或暫時性腦缺血 (TIA) 之病人：NIHSS 分數 ≥ 5 之病人以及接受血液溶栓治療 (thrombolysis) 之病人被排除在THALES試驗之外，且不建議這類病人使用Brilinta。可能的話，處理出血不要停止使用Brilinta。停止使用Brilinta可能增加隨後心血管事件的風險。治療ACS病人時併用之Aspirin每日維持劑量：在接受ACS病人時，Brilinta與每日維持劑量超過100 mg的Aspirin併用會降低Brilinta的有效性。在這些病人中，給予Aspirin治療量後，與Brilinta併用時，除非有特殊禁忌，Aspirin每日維持劑量應為75-100 mg。呼吸困難 (dyspnea)：如果病人有新發生、長時間或惡化性的呼吸困難且確定與Brilinta相關，如果可能的話，繼續使用Brilinta不要中斷。若病人發生難以承受的呼吸困難時，應考慮停止投予Brilinta並採取其他抗血小板藥物。ACS病人停用Brilinta之考慮：ACS之病人如停用Brilinta可能增加心肌梗塞、中風和死亡的風險。如果必須暫時停用Brilinta，要儘快重新開始。可能的話，在有重大出血危險的手術前5天中斷Brilinta治療；一旦出血恢復後Brilinta治療。緩慢型心律不整 (bradycardia)：Brilinta會造成心室停搏 (ventricular pause)。主要發生於ACS病人。心源性缺血性併用藥物減少心跳或影響心臟傳導等潛在危险因素所致。肝功能不全：Ticagrelor目前尚未在重度肝功能不全病人進行試驗。因此這些病人禁止使用。與強效CYP3A4抑制劑併用：Ticagrelor會被CYP3A4代謝，避免與強效CYP3A4抑制劑併用。急性缺血性腦中風或暫時性腦缺血：有極少數病例使用ticagrelor時出現急性缺血性腦中風 (非劑量反應TIA)。其特點是神經症候不真實，且功能不全或發覺缺血的小板減少與微血管病變血液學。TTP具有潛在致命性應立即進行包括血小板功能障礙治療。以血小板功能障礙試驗 (顯性者引起血小板低下 (heparin-induced thrombocytopenia, HIT)、HIT-2血小板功能試驗 (包括但不限於HIT-2試驗) 的陰性結果現在服用ticagrelor的病人。中樞神經性睡眠呼吸中止症 (central sleep apnea)：使用Brilinta之病人在上市後被報導發生中樞神經性睡眠呼吸中止症，包含陳-施氏呼吸 (Cheyne-Stokes respiration)。如有中樞神經性睡眠呼吸中止之疑慮，應考慮進一步臨床評估。【特殊族群使用】 老年人：老年人無須調整劑量。腎功能不全：腎功能不全病人無須調整劑量。肝功能不全：Ticagrelor目前尚未在重度肝功能不全病人進行試驗。因此這些病人禁止使用。中樞神經功能不全病人只有有限資料。未建議調整劑量，但使用 ticagrelor 時應特別謹慎。輕至中功能不全病人不需要調整劑量。懷孕：從使用Brilinta懷孕婦女個案報告可推測的數據，並未發現有重大出生缺陷、流產、對發育或胎兒有副作用等藥物相關的風險。授乳婦女：未有資料顯示ticagrelor或其代謝物是否存在於人乳，對哺乳中嬰兒或母乳製成的影響。在Brilinta治療期間不建議哺乳。兒童族群：目前尚未滿18歲以下兒童使用Ticagrelor的安全性及療效。目前尚無可用資料。【不良反應】 出血及呼吸困難。【使用說明書說明書及注意事項，詳細仿單資料備索。】

北市衛藥字第1106410號

BRILINTA™
ticagrelor tablets

臺灣阿斯特捷利康股份有限公司 台北市敦化南路二段207號21樓
電話：(02) 2378-2390 傳真：(02) 2377-0914 <http://www.astrazeneca.com.tw>

AstraZeneca

PRADAXA PROTECTS YOU PRADAXA 保護您



普格達™ 膠囊 75 毫克 Pradaxa® Capsules 75mg / 普格達™ 膠囊 110 毫克 Pradaxa® Capsules 110mg / 普格達™ 膠囊 150 毫克 Pradaxa® Capsules 150mg

【適應症】 1. 用於靜脈血栓高危險群病患，以預防其於接受大血管手術後之靜脈血栓栓塞症(VTE)。2. 預防非瓣膜性心房纖維顫動病患發生中風與全身性栓塞。3. 急性深層靜脈血栓(DVT) 及/或肺栓塞 (PE) 之治療。說明:各適應症的詳細用法用量請參見用法用量段落。 **【用法用量】** 本藥須由醫師處方使用。用法Pradaxa®空腹或飯後服用均可。應以一杯開水配服，以利到達胃部。如果病患出現胃腸道症狀，建議可隨餐併用Pradaxa®或投予質子幫浦抑制劑如pantoprazole。患者告知病患，勿將膠囊打碎，因為這可能增加出血風險。用於靜脈血栓高危險群病患，以預防其於接受大血管手術後之靜脈血栓栓塞症(VTE) 普格達置換手術後的病患 Pradaxa®的建議使用劑量為每次口服150 mg (兩顆75 mg膠囊)或220 mg (兩顆110 mg膠囊)，一天一次。治療應於手術結束後1-4小時內開始 (口服一顆膠囊)，隨後每次服用2顆膠囊，一天一次，總計10天。 瓣膜置換手術後的病患 Pradaxa®的建議使用劑量為每次口服150 mg (兩顆75 mg膠囊)或220 mg (兩顆110 mg膠囊)，一天一次。治療應於手術結束後1-4小時內開始 (口服一顆膠囊)，隨後每次服用2顆膠囊，一天一次，總計28-35天。 預防非瓣膜性心房纖維顫動病患發生中風與全身性栓塞 建議使用劑量為每次口服110-150 mg，一天兩次，空腹或飯後服用均可，視病人個人條件及臨床狀況使用之。一顆150mg膠囊可用兩顆75mg膠囊代替。急性深層靜脈血栓(DVT) 及/或肺栓塞 (PE) 之治療成人建議於注射型抗凝劑治療至少五天之後，使用一天300 mg劑量的PRADAXA® (每次口服一顆150 mg膠囊，一天兩次)，持續治療6個月。 **【禁忌症】** 已知對dabigatran或dabigatran etexilate或本產品的任一賦型劑過敏、嚴重腎功能受損 (肌酐清除率 < 30 ml/min)、有出血症狀表現、存在出血因素、或有自發性或藥物性止血功能受損的病患、存在臨床嚴重出血風險的器質性病變。包括過去6個月內發生的出血性中風、同時接受全身性ketocoazole, cyclosporine, itraconazole治療、人工關節置換。 **【警誡及注意事項】** 肝功能不全、出血風險、與P-糖蛋白誘發劑的交互作用等 **【不良反應】** 本藥品的不良反應與dabigatran etexilate的藥理作用相關，且為不同人體器官發生出血性中風、同時接受全身性ketocoazole, cyclosporine, itraconazole治療、人工關節置換。 **【警誡及注意事項】** 肝功能不全、出血風險、與P-糖蛋白誘發劑的交互作用等 Pradaxa 150mg 血管藥輸字號0254593號 Pradaxa 110mg 血管藥輸字號0254593號 Pradaxa 75mg 血管藥輸字號026233號

遠程管注注射液/輸注液 Praxbind® Solution for injection/infusion

【適應症/用途】 Praxbind®為具一經專一性的dabigatran直接作用劑。適用於接受管控性(Pradaxa®)治療而需要快速反轉dabigatran抗凝血作用的成人病人: 1.供緊急手術/緊急程序使用(urgent procedure)。2.於戒癮或控制不良的出血時使用。 **【用法用量】** Praxbind®建議劑量為5g (2 x 2.5 g/50ml)。Praxbind® (2x2.5 g/50 ml)應以靜脈注射方式施用，分兩次，各於5-10分鐘內完成連續輸注或是快速靜脈注射。重新開始使用抗凝血治療。施用Praxbind® 24小時後，若病人臨床狀況穩定且已獲充分止血，即可再重啟管控性(Pradaxa®)治療。施用Praxbind®後，若病人臨床狀況穩定且已獲充分止血，也可開始使用其他抗凝血治療 (例如: 低分子量肝素)。缺乏抗凝血治療時，病人會因瀰在疾病或狀況而有發生血栓風險的可能性。 **【禁忌症】** 無。 **【特殊警語及注意事項】** Idarucizumab會與dabigatran發生專一性結合，反轉其抗凝血作用，但不會反轉其他抗凝血劑的作用。Praxbind®治療可搭配醫療上允許的標準支撐性措施使用。過敏、遺傳性果糖不耐症、血栓檢查事件、凝血參數再度升高、可逆性。 **【副作用】** Praxbind®經納入224名第一期試驗之志願受試者及第三期試驗之503名病人為對象，評估Praxbind®之安全性。其中，第三期試驗病人對象為發生控制不良的出血，或需要接受緊急手術或醫療措施，並且正使用管控性(Pradaxa®)治療者。試驗中並未觀察到不良反應。 **【藥商】** 台灣百靈佳格翰股份有限公司 **【地址】** 台北市中山區民生東路三段2號12樓 **【製造廠】** Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany **【國外藥品許可證持有者】** Boehringer Ingelheim International GmbH **【備醫藥專業人員參考，處方藥物請參考衛生福利部核准仿單說明書】** Praxbind 南部藥輸字號001041號

北市藥輸字號110050136號



台灣百靈佳格翰股份有限公司
台北市中山區民生東路三段2號12樓 電話: (02) 25032636
光電: (02) 25036888·中區: (04) 23511828·南區: (07) 3900708



Day 2 : Live Transmission V & Lecture

Sunday (W7), January 8, 2023 08:30-10:15

R 201

Live Site : Kaohsiung Chang-Gung Memorial Hospital

Chairs :

I-Chang Hsieh (謝宜璋), Chi-Hung Huang (黃啓宏), Ching-Chang Fang (方慶章),
Osamu Iida, *Ken Kozuma

Commentators :

*Bryan Ping-Yen Yan, Kuang-Te Wang (王光德), Chung-Ho Hsu (徐中和),
Cheng-Hsueh Wu (吳承學), Mao-Shin Lin (林茂欣), Chun-Chi Chen (陳俊吉)
Chen-Rong Tsao (曹承榮), Wei-Kung Tseng (曾維功)

IVUS/OCT Commentators :

Chia-Pin Lin (林佳濱), Ming-Yun Ho (何明昀)

Room 1 : Transradial Carotid Stenting

Operator : Hon-Kan Yip (葉漢根) / Pei-Hsun Sung (宋沛勳)

08:30-10:15

Room 2 : PAOD – SFA long Occlusive Lesion by JetStream

Operator : Shu-kai Hsueh (薛書凱) / Wen-Jung Chung (鍾文榮)

Room 3 : Transbradial RDN

Operator : Tzung-Dau Wang (王宗道) / Cheng-I Cheng (鄭正一)

09:15-09:25

Lecture 5 : Taiwan PAD Consensus Update

Speaker : Jen-Kuang Lee (李任光)

Day 2 : Live Transmission VI & Lecture

Sunday (W7), January 8, 2023 10:15-12:00

R 201

Live Site : Kaohsiung Chang-Gung Memorial Hospital

Chairs :

Hsien-Li Kao (高憲立), Tse-Min Lu (盧澤民), Ji-Hung Wang (王志鴻), Yasumi Igarashi

Commentators :

Kenya Nasu, Ji-Yan Chen (陳紀言), Xi Su (蘇晞), Cheng-Ting Tsai (蔡政廷),
Yi-Chih Wang (王怡智), Shih-Chi Liu (劉世奇), Zhih-Cherng Chen (陳志成),
Shih-Hung Chan (詹世鴻), Ying-Hsien Chen (陳盈憲), Hsin-Fu Lee (李信賦)

IVUS/OCT Commentators :

Chia-Pin Lin (林佳濱), Ming-Yun Ho (何明昀)

Room 1 : CTO – LAD Septal to Septal Collateral

Operator : Masahiko Ochiai / Hsiu-Yu Fang (方修御)

10:15-12:00

Room 2 : CTO – LAD in CABG

Operator : Chiung-Jen Wu (吳炯仁) / Chien-Ho Lee (李建和)

Room 3 : CTO- Sting ray for RCA

Operator : Po-Ming Ku (顧博明) / Cheng-I Cheng (鄭正一)

11:00-11:10

Lecture 6 : Asahi's New Penetration Wires: Gaia Next 4 and Conquest Pro 12 ST

Speaker : Shunsuke Matsuno

11:55-12:00

Closing

Chi-Hung Huang Secretary General, TSCI (黃啓宏秘書長)

TCT@TTT Highlights (I)

Saturday (W6), January 7, 2023 08:20-10:05 (GMT+8)

R 301

Friday (W5), January 6, 2023 19:20-21:05 (EST)

Virtual

Moderators :

*Gary S. Mintz, Ziad A Ali, I-Chang Hsieh (謝宜璋), Tien-Ping Tsao (曹殿萍)

Discussants :

Suzanne V. Arnold, Ajay J. Kirtane, Yuhei Kobayashi, Scott Lim, Mohamad A. Alkhoul, Shih-Hsien Sung (宋思賢), Mao-Shin Lin (林茂欣)

08:20	Opening Remarks Gary S. Mintz
08:23	FAME 3 Substudies: Clinical Outcomes Related to Anatomic vs. Functional Significance and Prognostic Value of Post-PCI FFR Yuhei Kobayashi
08:38	Discussion
08:43	CLASP II D Trial: A Randomized Comparison of Transcatheter Edge-to-Edge Repair Devices for Degenerative Mitral Regurgitation – Clinical Outcomes and Echo Findings Scott Lim
08:58	Discussion

TCT@TTT Highlights (I)

Saturday (W6), January 7, 2023 08:20-10:05 (GMT+8)

R 301

Friday (W5), January 6, 2023 19:20-21:05 (EST)

Virtual

09:03

Transcatheter Edge-to-Edge Repair in Patients with Severe Mitral Regurgitation and Cardiogenic Shock: Insights from the TVT Registry
Mohamad A. Alkhoul

09:18

Discussion

09:23

Mediators of Improvement in TAVR Outcomes Over Time: Insights from the STS-ACC TVT Registry
Suzanne V. Arnold

09:38

Discussion

09:43

Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial
Ajay J. Kirtane

09:58

Discussion

10:03

Closing Remarks
I-Chang Hsieh (謝宜璋)

TCTAP @ TTT

Saturday (W6), January 7, 2023 10:05-11:05 (GMT+8)

R 301

Saturday (W6), January 7, 2023 11:05-12:05 (KST)

Virtual

Moderators :

Seung-Jung Park, Duk-Woo Park, I-Chang Hsieh (謝宜璋), Guang-Yuan Mar (馬光遠)

Discussants :

Jung-Min Ahn, Do-Yoon Kang, Chi-Hung Huang (黃啓宏), Feng-Yu Kuo(郭風裕)

10:05	Welcome & Introductory Remarks Seung-Jung Park
Left Main	
10:05	What Really Matters in LM Bifurcation PCI: Concept or Technique? Seung-Jung Park
10:17	How to Optimize LM Bifurcation PCI? Tips and Tricks Do-Yoon Kang
New Data from AMC	
10:29	Routine Functional Testing or Standard Care in High Risk PCI: The POST-PCI Trial Duk-Woo Park
10:41	PCI vs CABG in Multivessel Disease: Extended Follow-up of the BEST Trial Jung-Min Ahn
10:53	Interactive Panel Discussion
11:05	Closing I-Chang Hsieh (謝宜璋)

CCT@TTT

Saturday (W6), January 7, 2023 11:05 – 12:05(GMT+8)

R 301

Saturday (W6), January 7, 2023 12:05 – 13:05(JST)

Virtual

Chairs :

Yasumi Igarashi, *Takafumi Tsuji, Wen-Lieng Lee (李文領), Chiung-Jen Wu (吳炯仁)

Panelists :

Maoto Habara, Katsuyuki Hasegawa, Shunsuke Matsuno, Kenya Nasu, Ping-Han Lo (羅秉漢),
Feng-Yu Kuo (郭風裕)

11:05	Opening Wen-Lieng Lee (李文領)
11:08	Revaluation of Importance of Antegrade CTO PCI Maoto Habara
11:20	Q & A
11:23	Imaging Modality for Antegrade CTO PCI Katsuyuki Hasegawa
11:35	Q & A
11:38	Penetration Plane Method: New Concept for Guide Wire Manipulation in CTO PCI Shunsuke Matsuno
11:50	Q & A
11:53	Case presentation: Antegrade CTO PCI Using Penetration Plane Method Kenya Nasu
12:05	Q & A
12:08	Closing Yasumi Igarashi

Case Competition (II)

Saturday (W6), January 7, 2023 08:30-12:00

R 401

 08:30 PM WELCOME & OPENING Ching-Chang Fang (方慶章)
 (every case : presentation- 9 minutes, discussion- 3 minutes, total 14cases)

A. Coronary CTO :

Moderators : Ching-Chang Fang (方慶章), Jun-Ting Liou (劉俊廷), Yi-Chih Wang(王怡智),
 Chun-Hung Su (蘇峻弘)

Panelists : Chiung-Ray Lu (盧炯睿), Chun-Yuan Chu (朱俊源), Ming-Jer Hsieh (謝明哲), Yu-Cheng Hsu (許育誠)

 08:35 Case I Presentation Dan-Ying Lee (李丹英)
 08:47 Case II Presentation Chang-Yi Lin (林長逸)
 08:59 Case III Presentation Jiunn-Wen Lin (林俊玟)
 09:11 Case IV Presentation Wei-Cheng Chang (張偉政)
 09:23 Case V Presentation Yu-Ling Hsu (許毓幹)
 09:35 Case VI Presentation Hsu-Chung Lo (羅勛中)
 09:47 The Best Challenging Cases & Announcement-Vote (First and second place winners)

E. Structural Heart :

Moderators : Chih-Yuan Fang (方志元), Kae-Woei Liang (梁凱偉), Chin-Chang Cheng (鄭錦昌),
 Ke-Wei Chen (陳科維)

Panelists : Wei-Ta Chen (陳威達), Chi-Yen Wang (王奇彥), Shih-Yu Huang (黃爽毓), Tzu-Hsing Lin (林子翔)

 10:00 Case I Presentation Huan-Chiu Lin (林煥湫)
 10:12 Case II Presentation Po-Jung Chen (陳柏蓉)
 10:24 Case III Presentation Su-Chan Chen (陳素真)
 10:36 Case IV Presentation Chun-Hung Su (蘇峻弘)
 10:48 The Best Challenging Cases & Announcement-Vote (First place winner)

F. Carotid/EVT :

Moderators : Chung-Ho Hsu (徐中和), Yung-Hua Chu (朱永譚), Wei-Chun Chang (張偉俊),
 Shu-kai Hsueh(薛書凱)

Panelists : I-Chih Chen (陳怡芝), Huai-Wen Liang (梁懷文), Yung-Ming Chang (張永明),
 Chun-Chin Chang (張俊欽)

 11:00 Case I Presentation Chung-Ying Lu (呂忠穎)
 11:12 Case II Presentation Donna Shu-Han Lin(林姝含)
 11:24 Case III Presentation Liang-Hsu Liu (劉亮照)
 11:36 Case IV Presentation Po-Hsueh Su (蘇柏學)
 11:48 The Best Challenging Cases & Announcement-Vote (First place winner)

11 :58 CLOSING REMARK and ADJOURN Chung-Ho Hsu (徐中和)

Luncheon Symposium (Abbott)

Saturday (W6), January 7, 2023 12:10-13:20

R 201

2023 TAIWAN TRANSCATHETER THERAPEUTICS
ABBOTT LUNCHEON

Complex with Confidence

January 7, 2023 (Sat.)

12:10-13:20

臺大國際會議中心R201



Panelists: 曹殿萍 醫師、劉尊香 醫師、黃偉春 醫師、宋思賢 醫師、Prof. Bryan Yan
振興醫院 台中榮總 高雄榮總 臺北榮總 香港中文大學威爾斯親王醫院

TIME	TOPIC	
12:10-12:15	Opening Remarks	MODERATOR 李文領 理事長 台中榮總
12:15-12:30	Insight On the PCI Future 2023	SPEAKER 林 賀 醫師 香港屯門醫院 MODERATOR 林茂欣 醫師 臺大醫院
12:30-12:35	Panel Discussion	All
12:35-12:50	How to Optimize Complex PCI with OCT Ulteon	SPEAKER Dr.Masahiko Ochiai Showa University Northern Yokohama Hospital MODERATOR 吳炯仁 醫師 高雄長庚
12:50-12:55	Panel Discussion	All
12:55-13:10	Optimized Daily Practice with Resting Full-Cycle Ratio (RFR)	SPEAKER 任昺龍 醫師 振興醫院 MODERATOR 王光德 醫師 台東馬偕
13:10-13:15	Panel Discussion	All
13:15-13:20	Closing Remarks	MODERATOR 謝宜璋 醫師 林口長庚

Luncheon Symposium (Biosensors)

Saturday (W6), January 7, 2023 12:10-13:20

R 301

Power Design Power Life Total Solution for STEMI Patients

Date : 7 Jan 2023 (SAT)
Time : 12:15-13:15
Venue: NTUH International Convention Center (Room 301)

Chairman: Dr. Paul KAO, Hsien-Li 高憲立 (TW)
Moderator (PART I): Dr. CHEN, Ching-Pei 陳清埤 (TW)

12:15-12:30 **Mortality Benefits of BA9 Eluting Stents in Patient with Myocardial Infarction** Prof. Keith OLDROYD
UK

12:30-12:45 **Latest Updates on BioFreedom STEMI Registry & Local Clinical Experiences** Dr. LIN Po-Lin
林柏霖
TW

Moderator (PART II): Dr. CHAO, Ting-Hsing 趙庭興 (TW)

12:45-13:00 **New BioFreedom Ultra – Stent Design Makes Difference on Complex Lesions** Dr. LEE Kang Yin
李耿淵
HK

13:00-13:15 **Introduction & Clinical Updates of Penumbra CAT RX** Dr. CHUI Ka Lung
徐家龍
HK

Luncheon Symposium (Daiichi Sankyo)

Saturday (W6), January 7, 2023 12:10-13:20

R 401

Optimal antiplatelet therapy in East Asian patients

Date : 7th January, 2023 (Saturday)

Venue : 台大國際會議中心 401 會議室

Address : 台北市中正區徐州路2號

Co-Chaired by : 詹貴川 醫師 中山醫學大學附設醫院 / 方慶章 醫師 台南市立醫院

Agenda

12:10 **Chair :** 詹貴川 醫師 中山醫學大學附設醫院

12:15 **Opening Remarks**

Speaker : Dr. Takashi Kubo 久保 隆史 醫師 Naga Municipal Hospital

12:15 **Chair :** 詹貴川 醫師 中山醫學大學附設醫院

12:40 **The relationship between timing of prasugrel pretreatment
and in-stent thrombus for ACS**

Speaker : 林彥宏 醫師 台灣大學醫學院附設醫院

12:40 **Chair :** 方慶章 醫師 台南市立醫院

13:10 **Optimized Antiplatelet Therapy with Asian-dose Prasugrel
in Taiwanese ACS Patients - Base on HANC Score from the
Switch Study**

13:10 **詹貴川 醫師 中山醫學大學附設醫院 / 方慶章 醫師 台南市立醫院**

13:25 **Panel discussion** **All Participants**

13:25 **Chair :** 方慶章 醫師 台南市立醫院

13:30 **Closing Remarks**

Cross-Strait Symposium (Mandarin Session)

Saturday (W6), January 7, 2023 13:30-15:40

R 301

Chairs:

Min-Ji Charng (常敏之), Yan Wang (王焱), Shao-Liang Chen (陳紹良), Ya-Wei Xu (徐亞偉),
Ching-Chang Fang (方慶章)

Commentators:

Ji-Yan Chen (陳紀言), Liang-Long Chen (陳良龍), Yi-Da Tang (唐熠達), Xi Su (蘇晞),
Mu-Yang Hsieh (謝慕揚), Yu-Cheng Hsu (許育誠), Jong-Shiuan Yeh (葉仲軒)

13:30

Opening

Min-Ji Charng (常敏之)

13:35

Image Guided PCI for Calcified Lesion

Michael Yu-Chih Chen (陳郁志)

13:53

Discussion

13:58

When and How to Use Guiding Extension Catheter for Rotational Atherectomy

Ji-Hung Wang (王志鴻)

14:16

Discussion

14:21

Development and Clinical Practice of Microport Rotation System

Chang-Ling Li (李長嶺)

Cross-Strait Symposium (Mandarin Session)

Saturday (W6), January 7, 2023 13:30-15:40

R 301

14:39

Discussion

14:44

Break time

14:54

How to Use Excimer Coronary Laser Atherectomy for the Severely Calcified Lesion

Wen-Liang Lee (李文領)

15:12

Discussion

15:17

Unforgettable Case of Rotational Atherectomy

Qiang Xue (薛强)

15:35

Discussion

15:40

Closing

Wei-Chun Huang (黃偉春)

CVIT@TTT

Saturday (W6), January 7, 2023 15:50 – 17:00 (GMT+8)

R 301

Saturday (W6), January 7, 2023 16:50 – 18:00 (JST)

Virtual

What is the Significance of Invasive Pressure Wire in the Era of Angio Based FFR?

Chairs :

Shinjo Sonoda, Hitoshi Matsuo, Kuang-Te Wang (王光德), Hsu-Lung Jen (任昺龍)

Panelists :

Fumiyasu Seike, Chien-Hsun Hsia (夏建勳), Ming-Yun Ho (何明昀), Ching-Chang Huang (黃慶昌), Tao-Cheng Wu (吳道正), Chien-Boon Jong (楊欽文)

15:47

Opening

Shinjo Sonoda

15:50

Angio Based FFR is Sufficient (No Need for Invasive Pressure Wire)

Taku Asano

16:05

Q&A

16:10

Invasive Pressure Wire is Still Necessary

Takayuki Warisawa

16:25

Q&A

CVIT@TTT

Saturday (W6), January 7, 2023 15:50 – 17:00 (GMT+8)

R 301

Saturday (W6), January 7, 2023 16:50 – 18:00 (JST)

Virtual

How do You Use Angio Based FFR and Invasive Pressure Wire in Your Daily Clinical Practice? Case-Based Discussion

16:30

Case 1 (Taiwan Experience)

Ching-Chang Huang (黃慶昌)

16:40

Case 2 (Japan Experience)

Yoshinori Kanno

16:50

Panel Discussion

17:00

Closing

Kuang-Te Wang (王光德)

Structural Symposium- Transcatheter Mitral Valve Replacement

Saturday (W6), January 7, 2023 13:30-17:00

R 401

13:30	Opening Wen-Lieng Lee (李文領)
13:35	Echocardiographic Evaluation for Severe MR: Transcatheter Repair or Replacement Moderator : Shih-Hsien Sung (宋思賢) Speaker : Ching-Wei Lee (李慶威)
13:55	Q & A
14:00	Tendyne TMVI: Patient Selection and Case-in-a-box Moderator : Mao-Shin Lin (林茂欣) Speaker : Fabien Praz
14:40	Q & A
14:45	Surgeon's Prospective in Treatment of Mitral Valve Disease in Transcatheter Era Moderator : Jhieh-Yuan Shih (施志遠) Speaker : I-Chen Chen (陳怡誠)
15:05	Q & A
15:10	Intrepid TMVI Moderator : Chin-Chang Cheng (鄭錦昌) Speaker : Gilbert Tang
15:30	Q & A

Structural Symposium- Transcatheter Mitral Valve Replacement

Saturday (W6), January 7, 2023 13:30-17:00

R 401

15:35

Mitral Valve in MAC

Moderator : Ying-Hwa Chen (陳嬰華)

Speaker : Luigi Pirelli

15:55

Q & A

16:00

Mitral Valve in Valve

Moderator : Wei-Hsian Yin (殷偉賢)

Speaker : Cheng-Han Li (李政翰)

16:20

Q & A

16:25

Mitral Valve in Ring and LAMPOON Procedure

Moderator : Cheng-Chung Cheng (鄭正忠)

Speaker : Yung-Tsai Lee (李永在)

16:45

Q & A

16:50

Closing

Yun-Ching Fu (傅雲慶)

Evening Symposium (Bayer)

Saturday (W6), January 7, 2023 17:10-18:10

R 201



TTT 2023 EVENING SYMPOSIUM HOLISTIC PROTECTION FOR YOUR PATIENTS WITH CARDIOVASCULAR DISEASES


Date: 2023/1/7 (Sat.)

Time: 17:10-18:10

Location: 台大國際會議中心 R201會議室

MEETING AGENDA

Time	Subject	Speaker	Moderator
17:10~17:15	Opening Remarks	郭風裕 主任 高雄榮總	
17:15~17:35	Advanced Management of Worsening Heart Failure Event for HFREF Patients: Implications from VICTORIA	劉銘恩 主任 新竹馬偕	郭風裕 主任 高雄榮總
17:35~17:55	A Safe and Simple Choice for Elderly AF Patients	吳卓鎔 醫師 臺大醫院	郭風裕 主任 高雄榮總
17:55~18:05	Panel Discussion	劉銘恩 主任 吳卓鎔 醫師	郭風裕 主任
18:05~18:10	Closing Remarks	郭風裕 主任 高雄榮總	

VERQUVO® 維可沃® 精確降尿酸

維可沃® 維可沃® 是一種口服降尿酸藥物，能顯著降低尿酸水平，預防痛風發作。其作用機制獨特，能直接抑制尿酸生成，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 具有優越的安全性，不會引起尿酸鹽沉澱，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 是一種口服降尿酸藥物，能顯著降低尿酸水平，預防痛風發作。其作用機制獨特，能直接抑制尿酸生成，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 具有優越的安全性，不會引起尿酸鹽沉澱，且不會引起尿酸鹽沉澱。

維可沃® 維可沃® 是一種口服降尿酸藥物，能顯著降低尿酸水平，預防痛風發作。其作用機制獨特，能直接抑制尿酸生成，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 具有優越的安全性，不會引起尿酸鹽沉澱，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 是一種口服降尿酸藥物，能顯著降低尿酸水平，預防痛風發作。其作用機制獨特，能直接抑制尿酸生成，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 具有優越的安全性，不會引起尿酸鹽沉澱，且不會引起尿酸鹽沉澱。

維可沃® 維可沃® 是一種口服降尿酸藥物，能顯著降低尿酸水平，預防痛風發作。其作用機制獨特，能直接抑制尿酸生成，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 具有優越的安全性，不會引起尿酸鹽沉澱，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 是一種口服降尿酸藥物，能顯著降低尿酸水平，預防痛風發作。其作用機制獨特，能直接抑制尿酸生成，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 具有優越的安全性，不會引起尿酸鹽沉澱，且不會引起尿酸鹽沉澱。

維可沃® 維可沃® 是一種口服降尿酸藥物，能顯著降低尿酸水平，預防痛風發作。其作用機制獨特，能直接抑制尿酸生成，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 具有優越的安全性，不會引起尿酸鹽沉澱，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 是一種口服降尿酸藥物，能顯著降低尿酸水平，預防痛風發作。其作用機制獨特，能直接抑制尿酸生成，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 具有優越的安全性，不會引起尿酸鹽沉澱，且不會引起尿酸鹽沉澱。

維可沃® 維可沃® 是一種口服降尿酸藥物，能顯著降低尿酸水平，預防痛風發作。其作用機制獨特，能直接抑制尿酸生成，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 具有優越的安全性，不會引起尿酸鹽沉澱，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 是一種口服降尿酸藥物，能顯著降低尿酸水平，預防痛風發作。其作用機制獨特，能直接抑制尿酸生成，且不會引起尿酸鹽沉澱。維可沃® 維可沃® 具有優越的安全性，不會引起尿酸鹽沉澱，且不會引起尿酸鹽沉澱。

Evening Symposium (Novartis)

Saturday (W6), January 7, 2023 17:10-18:10

R 301



		
07.JAN.(Sat)	17:10-18:10	臺大國際會議中心 R301
 SPEAKER 林柏霖 醫師 新竹馬偕心臟內科 •新竹馬偕紀念醫院 心臟內科資深主治醫師 •中華民國心臟學會 副秘書長	 MODERATOR 李文領 醫師 臺中榮總心臟內科 •臺灣介入性心臟血管 醫學會理事長 •臺中榮民總醫院心臟血管 中心部主任 •國立中興大學醫學系 內科專任教授	
TIME	TOPIC	
17:10-17:15	Opening	
17:15-17:55	Take the Action ASAP: How Can We Reverse Heart Failure Progression Through Timely Action	
17:55-18:05	Discussion	
18:05-18:10	Closing	



Evening Symposium (Shockwave Medical)

Saturday (W6), January 7, 2023 17:10-18:10

R 401



Evening Symposium



Shockwave IVL Launch

Date : Jan 7, 2023 Saturday

Site: 2023 TTT , NTUH International Convention Center, Taipei

Time	Activity	Speaker	Moderator and Panelist
5:10pm-5:15pm	Opening Remarks	Dr. Paul Hsien-Li Kao National Taiwan University Hospital	
5:15pm-5:30pm	Intravascular Lithotripsy (IVL) Introduction and Algorithmic Approach (Virtual)	Dr. Honton Benjamin Fajadet Group in Clinique Pasteur, Toulouse France	Moderator: Dr. Paul Hsien-Li Kao Dr. Wei-Hsian Yin
5:30pm-5:40pm	IVL Case Sharing From Taipei Taiwan – Rota-Lithotripsy – A Novel Strategy for Calcified Coronary Lesions (on site)	Dr. Wei-Hsian Yin Heart Center, Cheng Hsin General Hospital, Taipei	Panelist: Dr. Chi-Jen Chang Chang Gung Memorial Hospital Dr. I-Chang Hsieh Chang Gung Memorial Hospital Dr. Jung-Cheng Hsu Far Eastern Memorial Hospital
5:40pm-6:00pm	Fajadet Group IVL Case Sharing From Toulouse France (Video Case and Virtual Live)	Dr. Honton Benjamin Fajadet Group in Clinique Pasteur, Toulouse France	Dr. Chi-Hung Huang Cathay General Hospital Dr. Chih-Hung Wang Hualien Tzu Chi Hospital
6:00pm-6:08pm	Q&A		
6:08pm-6:10pm	Wrap-Up	Dr. Wei-Hsian Yin Cheng Hsin General Hospital	



Coronary Intravascular Lithotripsy (IVL) LET'S GET CRACKING.

PREDICTABLY SAFE
Establish a new standard of care for safe calcium modification by reducing the risk of perforations and other complications to make procedures more predictable and efficient.

DISTINCTLY INTUITIVE
Optimally modify calcium from the very first case via a unique mechanism of action in an intuitive platform.

CONSISTENTLY EFFECTIVE
Active excellent lumen gains and stent expansion consistently despite the calcium morphology – whether superficial or deep, concentric or eccentric, and short or long lesions.

CONTACT US

Manufacturer:
Shockwave Medical,
Santa Clara, CA US

Distribution:
VAS Solutions, Taiwan

Keynote Speech (II)

Sunday (W7), January 8, 2023 08:30-09:40

R 301

08:30	Opening Wen-Lieng Lee (李文領)
08:35	Intracoronary Calcium: From Microcalcification to Stent Underexpansion Moderator : Wen-Lieng Lee (李文領) Speaker : *Gary S. Mintz
08:50	Discussion
08:55	PCI for Reduced LV Function Moderator : Ji-Hung Wang (王志鴻) Speaker : *Frankie Tam
09:10	Discussion
09:15	3-Year Follow-Up of DEFINITION II Trial Moderator : Wei-Hsian Yin (殷偉賢) Speaker : Shao-Liang Chen (陳紹良)
09:30	Discussion
09:35	Closing Wei-Hsian Yin (殷偉賢)

ENCORE SEOUL@TTT

Sunday (W7), January 8, 2023 09:50-10:50 (GMT+8)

R 301

Sunday (W7), January 8, 2023 10:50-11:50 (KST)

Virtual

Current DAPT Strategy after DES Implantation in ACS Patients

Moderators :

*Myeong-Ki Hong, Wen-Lieng Lee (李文領)

Panelists :

Young Won Yoon, Jung Min Ahn, Choongki Kim,

Yu-Chen Wang (王宇澄), Chun-Hung Su (蘇峻弘), Huai-Wen Liang(梁懷文)

09:50	Opening Wen-Lieng Lee (李文領)
09:51	P2Y12 Inhibitor Monotherapy in ACS Patients: Which Agent? Joo-Yong Hahn
09:59	Antiplatelet Therapy for ACS: DAPT vs. P2Y12 Inhibitor Monotherapy Yi-Heng Li (李貽恆)
10:07	Discussion
10:20	Dose Reduction of Prasugrel in ACS PCI Kyung Woo Park
10:28	Pharmacogenetic SWITCH in Anti-platelet Therapy for ACS Population : From Asian's View Ping-Yen Liu (劉秉彥)
10:36	Discussion
10:49	Closing Myeong-Ki Hong

APSIC@TTT

Sunday (W7), January 8, 2023 11:00-12:00

R 301

Complex High Risk PCI: THE CASE I WILL NEVER FORGET!

Moderators:

Wen-Lieng Lee (李文領), I-Chang Hsieh (謝宜璋)

Chairpersons:

Ashok Seth, Chi-Jen Chang (張其任)

Discussants:

Teguh Santoso, Rajinikanth Rajagopal, Chieh-Shou Su (蘇界守), Hsu-Lung Jen (任昺龍)

11:00	Opening Ashok Seth
11:02	My Satisfying Success: Where Others Had Failed Earlier! Ashok Seth
11:10	Discussion
11:16	My Eureka Moment: I Succeeded Where I Had Failed Earlier! Fazila Malik
11:24	Discussion
11:30	My Nightmare of a Complication: Thankfully I Salvaged It! Satoru Sumitsuji
11:38-	Discussion
11:44	I Could Save Him: A Really Difficult Surgical Turn Down! Michael Lee
11:52	Discussion
11:58	Closing Wen-Lieng Lee (李文領)

Case Competition (II)

Sunday (W7), January 8, 2023 08:30-12:00

R 401

08:30 WELCOME & OPENING Cheng-Han Li (李政翰)
(every case : presentation- 9 minutes, discussion- 3 minutes, total 14cases)

B. CHIP :

Moderators : Cheng-Han Li (李政翰), Jiunn-Cherng Lin (林俊呈), Chieh-Shou Su (蘇界守),
Po-Chao Hsu(許哲超)

Panelists : Kuan-Yu Chen (陳冠宇), Chen-Wei Huang (黃成偉), Yeh-Peng Chen (陳業鵬), Hsu-Ping Wu (吳敘平)

08:35 Case I Presentation Karen Pui Shan SHEK (石珮珊)
08:47 Case II Presentation Amy Ling Jing (林靜)
08:59 Case III Presentation Hao-Yun Chang (張皓雲)
09:11 Case IV Presentation Chien-Po Huang (黃堅波)
09:23 Case V Presentation Szu-Chi Chien (簡思齊)
09:35 The Best Challenging Cases & Announcement-Vote (First place winner)

C. Coronary Complications :

Moderators : Chuen-Den Tseng (曾春典), Chien-Ming Huang (黃建銘), Chih-Hung Lai (賴志泓),
Hsing-Ya Chang (張興亞)

Panelists : Yuan-Po Yang (楊淵博), Yueh-Chung Chen (陳鉞忠), Yu-Cheng Kao (高瑜成), Jiunn-Wen Lin (林俊茲)

09:45 Case I Presentation Chih-Yang Lin (林馳揚)
09:57 Case II Presentation Chiao-Hsiang Chang (張喬翔)
10:09 Case III Presentation Yan-Siou Chen (陳彥秀)
10:21 Case IV Presentation Zheng-Wei Chen (陳政璋)
10:33 Case V Presentation Chi-Tung Chen (陳琦棟)
10:45 Case VI Presentation Hsuan-Ling Tseng (曾宣靈)
10:57 The Best Challenging Cases & Announcement-Vote (First and second place winners)

D. Image/Physiology :

Moderators : Ming-Hsiung Hsieh (謝敏雄), Wei-Chun Chang (張偉俊), Lung-Ching Chen (陳隆景),
Hsin-I Teng (鄧欣一)

Panelists : Meng-Hsiu Chiang (江孟修), Chun-Cheing Wang (王駿丞), Yu-Wei Chen (陳昱璋),
Hsing-Long Yeh(葉勳龍)

11:10 Case I Presentation Cheng-Cheng Kan (甘承正)
11:22 Case II Presentation Shih-Chung Chen (陳世中)
11:34 Case III Presentation Jian-Kuan Yeh (葉建寬)
11:46 The Best Challenging Cases & Announcement-Vote (First place winner)

11:55 CLOSING REMARK and ADJOURN Ming-Hsiung Hsieh (謝敏雄)

Luncheon Symposium (AstraZeneca)

Sunday (W7), January 8, 2023 12:10-13:20

R 201

SAVE MORE LIVES



臺灣介入性心臟血管醫學會

Comprehensive Cardio-Renal and Life-Saving Protection for Patients with CVD

臺大醫院國際會議中心 R201

2023/01/08 (SUN.) 12:10-13:20

Agenda

Table with 2 columns: TIME and TOPIC. Contains 4 rows of event details including speaker and moderator names.

西藥廠 羅敏收 3 毫克、特 邁克 60mg (Ezetimibe/Simvastatin) Film-coated Tablets 60 mg, 60 mg... [Detailed text about the symposium's focus on cardiovascular and renal protection]

西藥廠 羅敏收 3 毫克、特 邁克 60mg (Ezetimibe/Simvastatin) Film-coated Tablets 60 mg, 60 mg... [Detailed text about the symposium's focus on cardiovascular and renal protection]

Luncheon Symposium (Pfizer)

Sunday (W7), January 8, 2023 12:10-13:20

R 301

Pfizer

8th Jun
TTT 2023
R301, 台大國際會議中心

12:10-12:15	Opening	Moderator 洪大川 醫師 / 馬偕醫院
12:15-12:45	Resolving dilemmas in anticoagulation for VTE- Bridging the knowledge gap	Speaker 陳怡芝 醫師 / 台南市立醫院 Moderator 洪大川 醫師 / 馬偕醫院
12:45-13:15	Peri-procedural use of DOACs in patients with AF undergoing cardiac interventions	Speaker 許智能 醫師 / 雲林台大醫院 Moderator 任昺龍 醫師 / 振興醫院
13:15-13:20	Discussion & Closing	Speaker ALL Moderator 任昺龍 醫師 / 振興醫院

PP-ELI-TWN-0630-202212

Luncheon Symposium (Biotronik)

Sunday (W7), January 8, 2023 12:10-13:20

R 401



-  Confirmed clinical safety and efficacy*
-  Fast Magnesium resorption time
-  Better deliverability

State-of-the-Art PCI strategy: Step up the PCI practices


Date:2023/01/08 12:00-13:20 (GMT+8) 📍 Venue:R401

Time	Topic	Presenter	Moderator
12:10-12:15	Welcome address	Dr. Hsien-Li Kao	
12:15-12:35	RMS and DCB - Leave Nothing Behind	Dr. Michael Joner	Dr. I-Chang Hsieh
12:35-12:45	Panel Discussion	Dr. Chi-Hung Huang Dr. Chun-Yao Huang Dr. Cheng-I Cheng Dr. Chieh-Shou Su Dr. Feng-Yu Kuo Dr. Hsu-Lung Jen Dr. Ming-Hsiung Hsieh Dr. Nien-Chung Chen	
12:45-13:00	Comparison of an Ultrathin strut with Thin strut	Dr. Chien-Yi Hsu	Dr. Chi-Jen Chang
13:00-13:15	Panel Discussion	Dr. Cheng-Han Lee Dr. Chun-Hung Su Dr. Chih-Chan Lin Dr. Hsin-Fu Lee Dr. Shao-Sung Huang Dr. Tse-Min Lu	
13:15-13:20	Summary & Closing	Dr. Wen-Liang Lee	

Ultimaster™ Tansei™

Sirolimus Eluting Coronary Stent System

Abluminal gradient coating



Innovative tip

Flexible stent design

Advanced shaft technology
with traditional Terumo hydrophilic coating

1 MONTH DAPT*

CE-mark approved for patients in need to stop DAPT earlier ①

* Patients should be maintained on clinically adequate post-procedural antiplatelet therapy according to the current guidelines. In case of need, dual antiplatelet therapy can be discontinued earlier, but not before one month.

① Ultimaster IFU



THE POWER OF

n

> 50,000 patients

Scan and download new Insight
of Complex PCI - MASTER DAPT
sub analysis - @EuroPCR 2022



Keynote Speech (I)

Sunday (W7), January 8, 2023 13:30-15:00

R 201

13:30

Opening

Tse-Min Lu (盧澤民)

13:30

How to Prevent and Treat Complications?

Moderator : Tse-Min Lu (盧澤民)

Speaker : Emmanouil S.Brilakis

13:45

Discussion

13:48

Future Aspects of Novel Mapping Technology in CTO PCI

Moderator : Chi-Jen Chang (張其任)

Speaker : Kenya Nasu

14:03

Discussion

14:06

The Landscape and Future of Percutaneous Mitral and Tricuspid Valve Interventions

Moderator : Hsien-Li Kao (高憲立)

Speaker : Eberhard Grube

14:21

Discussion

Keynote Speech (I)

Sunday (W7), January 8, 2023 13:30-15:00

R 201

14:24 **Ultra-Thin Coronary Stent Struts in Multivessel Disease**
Moderator : I-Chang Hsieh (謝宜璋)
Speaker : Patrick Serruys

14:39 **Discussion**

14:42 **Improving Survival in Cardiogenic Shock - Our Journey**
Moderator : Chi-Hung Huang (黃啓宏)
Speaker : Michael Lee

14:57 **Discussion**

15:00 **Closing**
Chi-Hung Huang (黃啓宏)

TCT@TTT Highlights (II)

Sunday (W7), January 8, 2023 15:00-17:00 (GMT+8)

R 201

Sunday (W7), January 8, 2023 07:00-09:00 (GMT+0)

Virtual

Moderators :

Eberhard Grube, Toshiro Shinke, Wen-Lieng Lee (李文領), Hsien-Li Kao (高憲立)

Discussants :

Ashok Seth, Teguh Santoso, Elmira Omerovic, Shao-Liang Chen, Joel Giblett,

Chi-Hung Huang (黃啓宏), Jung-Cheng Hsu (許榮城)

15:00	Opening Eberhard Grube
15:03	Percutaneous or Surgical Management of Post-Infarction Ventricular Septal Defects: The United Kingdom National Registry Joel Giblett
15:18	Discussion
15:22	Cutting Balloon to Optimize Predilatation for Stent Implantation: The COPS Randomized Trial Antonio Mangieri
15:37	Discussion
15:41	Impact of Underlying Causes of Acute Coronary Syndrome and 1-Year Outcomes After Percutaneous Coronary Intervention: Results From Optical Coherence Tomography Guided Primary Percutaneous Coronary Intervention Registry (TACTICS Registry) Toshiro Shinke
15:56	Discussion

TCT@TTT Highlights (II)

Sunday (W7), January 8, 2023 15:00-17:00 (GMT+8)

R 201

Sunday (W7), January 8, 2023 07:00-09:00 (GMT+0)

Virtual

16:00

**Pulmonary Artery Denervation for Pulmonary Arterial Hypertension:
A Sham-Controlled Randomised Trial**

Shao-Liang Chen

16:15

Discussion

16:19

**Contemporary Clinical and Echocardiographic Outcomes of 1000+
Patients Treated with MitraClip™ G4: Results from the EXPAND G4
Post Approval Study**

Ralph Stephan von Bardeleben

16:34

Discussion

16:38

**Survival after PCI or CABG for Left Main Coronary Disease:
A Report from the Swedish Coronary Angiography and Angioplasty
Registry**

Elmir Omerovic

16:53

Discussion

16:57

Closing

Wen-Lieng Lee (李文領)

Peripheral Interventions

Sunday (W7), January 8, 2023 13:30 - 15:30

R 301

13:30	Opening Cheng-Han Li (李政翰)
13:35	Peripheral Artery Disease- Unanswered Questions and Urgent Needs in 2023 Moderator : Hsu-Ping Wu (吳敘平) Speaker : Hsuan-Li Huang (黃玄禮)
13:50	Q & A
13:57	Multicenter Study for Peripheral Artery Disease- How We Started It Moderator : Jen-Kuang Lee (李任光) Speaker : Osamu Iida
14:12	Q & A
14:19	Advanced Skills and Techniques in Peripheral Artery Disease Intervention- Words of Wisdom Moderator : Po-Chao Hsu (許栢超) Speaker : Yoshimitsu Soga
14:34	Q & A
14:41	Deep Vein Arterialization- Can We do It Without Dedicated Devices? Moderator : Chun-Chi Chen (陳俊吉) Speaker : Steven Kum
14:56	Q & A

Peripheral Interventions

Sunday (W7) , January 8, 2023 13:30 - 15:30

R 301

15:03

Impact of COVID-19 Infection in Patients- Focusing on Limb Ischemia and Deep Vein Thrombosis

Moderator : Chi-Yen Wang (王奇彥)

Speaker : Chung-Ho Hsu (徐中和)

15:18

Q & A

15:25

Closing

Hsuan-Li Huang (黃玄禮)

Nurse/Tech Symposium (Mandarin Session)

Sunday (W7), January 8, 2023 13:30 - 15:40

R 401

13:30	Opening Wen-Lieng Lee (李文領)
13:35	LAVA ECMO 臨床使用對病人的幫助 Moderator : Yi-Ching Lin (林宜慶) Speaker : Jung-Cheng Hsu (許榮城)
14:00	Discussion
14:05	CTA 臨床應用之優點 (PCI, TAVI) Moderator : Cheng-Wei Chen (陳橙葦) Speaker : Mao-Shin Lin (林茂欣)
14:30	Discussion
14:35	Impella, PCPS, ECMO 病人使用的最好 Timing Moderator : Chin-Hui Tseng (曾欽輝) Speaker : Cheng-Hsueh Wu (吳承學)
15:00	Discussion
15:05	冠狀動脈慢血流發生機制及治療方法 Moderator : Ming-Ling Huang (黃銘玲) Speaker : Hsiu-Yu Fang (方修御)
15:30	Discussion
15:35	Closing Yi-Lain Kou (郭宜蘭)

Learning Center

Saturday & Sunday, January 7-8, 2023

(Medtronic) R 202

Medtronic Mini Lecture

Jan. 07, Saturday
Visit us at R202



新竹馬偕 林柏霖 14:30-15:00

Identify RDN candidates : what we learnt from the latest clinical evidence



汐止國泰 葉勳龍 15:00-15:30

Prevail DCB in bifurcation

Space is limited. Contact your Medtronic representative if you are interested in attending.

Jan. 07-08

Hands on



An exciting new experience for YOU!

- Using LINQ with MyCareLink home monitor for arrhythmia detection and reports transmission.
- Using kidney models to familiarize with RDN procedure.
- Observation samples of latest Coronary and PV products with clinical data.

Hands-on

- Renal denervation model




Hands-on

- LINQ hands on demo kit
- MyCareLink



Exhibition

- Bifurcation model
- Prevail DCB



Exhibition

- Chocolate PTA balloon catheter



Learning Center

Saturday & Sunday, January 7-8, 2023

(Abbott) R 203

2023 TAIWAN TRANSCATHETER THERAPEUTICS

ABBOTT LEARNING CENTER

 January 7-8, 2023 (Sat.)
 臺大國際會議中心R203


節目一

Case In A Box 精彩案例講座

節目二

OCT Hands On 光學斷層掃描應用

節目三

Vessel Closure 血管縫合模型演示

節目四

FFR 血流儲備分數儀器操作教學

Learning Center

Saturday & Sunday, January 7-8, 2023

(Boston Scientific) R 205



BSC Learning center 波波教室

Boston
Scientific
Advancing science for life™

01 / 07_{Sat.}

15:00 - 16:00 Backup support Rotablation

彰化基督教醫院
Dr. 簡思齊

Lecture 20分鐘

實際操作 40分鐘 (運用Simulator 實際操作GZ II backup support Rota)

01 / 08_{Sun.}

第一梯次
09:30 - 09:50 Optimizing lesion prepare, Limiting vessel damage, and Leaving nothing / right thing behind
第二梯次
10:10 - 10:30

臺大醫院
Dr. 林彥宏

Lecture 20分鐘 / 次 · 共兩次

14:00 - 15:00 Bifurcation stenting & Hands-on

臺北榮民總醫院
Dr. 盧澤民

Lecture 20分鐘

實際操作 40分鐘 (運用Bifurcation Model 實際操作Bifurcation Stenting Technique)

參加人員 | 一梯最多15人

人員限制 | 醫師及導管室技術人員

報名方式 | 請至BSC攤位由BSC業務協助報名

備註 | 請課程前5分鐘至BSC Learning center波波教室報到哦!



Learning Center

Saturday & Sunday, January 7-8, 2023

(Friends Biotec.) R 402

2023 TTT FRIENDS

New products introduction and hands on

Location

台大醫院國際會議中心

4F 402B Learning Center

Open Hour

1/7 0900-1600

1/8 0900-1600

ABOUT

- › “APT” AnyreachC™ & AnyreachP™
Guidewire
- › “APT” CONQUEROR™ Trap
Trapping balloon Catheter
- › “Elixir” DESyne X2
NOVOLIMUS ELUTING CORONARY STENT SYSTEM
- › “Meril” Myval
TRANSCATHETER HEART VALVE

歡迎蒞臨現場參與產品介紹及實際操作，即可參加抽獎活動

— Cordis —
DIAGNOSTIC CATHETERS



Our
Brands



Testing
results



Special
Shapes



Full
Portfolio

**Brands you trust. Shapes you need.
Quality you expect.**



Live Transmission Cases



臺北榮民總醫院

醫師 (M.D.)

王 壹 Yi Wang
宋偉廷 Wei-Ting Sung
林廷諭 Ting-Yu Lin
林淑馨 Su-Shen Lim
凌灝傑 Lo-Chien Lin
張祐寧 You-Ning Chang
莊明儒 Ming-Ju Chuang
郭鈞育 Jiun-Yu Kuo
傅苡倉 Yi-Tsang Fu
曾致學 Chih-Hsueh Tseng
蔡依霖 Yi-Lin Tsai
盧紀婷 Chi-Ying Lu

(依姓氏筆劃順序)

醫事人員 (Nurses&Technicians)

方若蓁 Jo-Chen Fang
李昇樺 Sheng-Hua Lee
李虹儀 Hung-Yi Lee
李儲華 Chwu-Hwa Lee
邱奕玲 Yih-Ling Chiou
郭宜蘭 Yi-Lan Kuo
陳珮瑜 Pei-Yu Chen
陳碧治 Pi-Chih Chen

黃建銘 Chien-Ming Huang
葉貴美 Kuei-Mei Yeh
鄭玟馨 Wen-Hsin Cheng

(依姓氏筆劃順序)

Date: 2022/01/07 08:30-12:00

Case 1: Right Coronary Artery Chronic Total Occlusion

Case 2: Right Coronary Artery Heavy Calcification

Case 3: Left Main Bifurcation

Case 4: Right Coronary Artery Chronic Total Occlusion

Case 5: Left Superficial Femoral Artery Chronic Total Occlusion

Case 1 : Right Coronary Artery Chronic Total Occlusion

Date: 2023/01/07

Operator: Dr. Tse-Min Lu (盧澤民)

Patient Demographics

Age : 58y/o

Gender : Female

Past Medical History

1. Hypertension
2. Uterine leiomyoma and adenomyosis
-s/p abdominal total hysterectomy on 2012/6/7

Clinical Presentation

Dyspnea on exertion for months

Risk Factors

Hypertension

Angiographic Findings

Coronary vascular anatomy (2022/11/15)

LM: patent

LAD: -M to -D: 70% stenosis

LCX: -D: 60% stenosis

RCA: -D: chronic functional total occlusion with auto-collateral flow from conus-branch to -PL and septal branch to -PL



Case 2 : Right Coronary Artery Heavy Calcification

Date: 2023/01/07

Operator: Dr. Chi-Jen Chang (張其任)

Patient Demographics

Age : 73y/o

Gender : Male

Past Medical History

1. Hepatocellular carcinoma with lung metastasis
2. Non ST-elevation myocardial infarction, triple-vessel-disease
- s/p DES *1 at LAD-M , DES *1 at LM-D to LAD-P on 2020/10/29
3. Liver cirrhosis, hepatitis B related, Child-Pugh class A
4. Chronic hepatitis B
5. Type 2 diabetes mellitus
6. Esophageal varices
7. Gastric ulcer and duodenal ulcers

Clinical Presentation

Abnormal cardiac enzyme, r/o secondary MI/NSTEMI, was noted during hospitalization for bilateral lobar pneumonia with suspect of Lenvatinib-related IRAE

Risk Factors

Type 2 diabetes mellitus

Angiographic Findings

Coronary vascular anatomy (2022/12/22)

LM: -M to LAD-P: instent patent

LAD: -P to -M: instent patent

LCX: luminal irregularity, -D: segmental stenosis up to 70%

RCA: -M to -D: diffuse stenosis up to 90% with heavy calcification and calcified nodule



Case 3 : Left Main Bifurcation

Date: 2023/01/07

Operator: Dr. Shao-Sung Huang (黃少嵩)

Patient Demographics

Age : 60 y/o

Gender : Male

Past Medical History

1. Coronary artery disease with triple vessel
 - LAD s/p DESx3 on 2013/6/3
 - RCA s/p DESx2 and BMSx1 on 2013/9/30
 - RCA ISR s/p DEBx1 on 2017/11/9
2. Hypertension
3. Hyperlipidemia

Risk Factors

Hyperlipidemia, Hypertension

Clinical Presentation

Chest tightness for months

Angiographic Findings

Coronary vascular anatomy (2022/12/01)

LM: -D: 50% stenosis

LAD: -P to -M: segmental stenosis up to 80% with calcified nodule, -M to -D: in-stent patent

LCX: Os to -P: diffuse stenosis up to 80%, -D: CTO s/p PCI and DES*1 at LCx -D on 2022/12/1

RCA: -P to -D: in-stent patent, -PDA: segmental stenosis up to 90%



Case 4 : Right Coronary Artery Chronic Total Occlusion

Date: 2023/01/07

Operator: Dr. Cheng-Han Li (李政翰)

Patient Demographics

Age : 66y/o

Gender : Male

Past Medical History

1. Type 2 DM, HBA1c=6.4 on 2022/12/6
2. Hypertension
3. Hyperlipidemia

Clinical Presentation

Exertional chest tightness for months

Risk Factors

Hyperlipidemia, Hypertension

Angiographic Findings


Coronary vascular anatomy (2022/12/14)

LM: patent

LAD: -P to -D: diffuse stenosis up to 90% s/p DES*3 at LAD-P to -D on 2022/12/14

LCX: luminal irregularity

RCA: -P: CTO with septal collateral from LAD



Case 5 : Left Superficial Femoral Artery Chronic Total Occlusion

Date: 2023/01/07

Operator: Dr. Cheng-Hsueh Wu (吳承學)

Patient Demographics

Age : 73 y/o

Gender : Male

Past Medical History

1. Pulmonary embolism
2. Hypertension
3. COPD
4. CAD with TVD
-s/p DES*1 at LAD -P to -M, DES*1 at LCx -M to -D, DES*2 at RCA -P to -D on 2022/11/11

Clinical Presentation

Left lower limb intermittent claudication for 2 months

Risk Factors

Hypertension, Coronary artery disease, Smoking(+) for 30yrs, 3 pack/day, Quit for 20yrs

Angiographic Findings

Left limb vascular anatomy (2022/11/11)

CFA: patent

SFA to Popliteal Artery: CTO with auto-collaterals and suspect thrombus formation


Popliteal Artery: patent

Anterior tibial artery: patent

Posterior tibial artery: patent

Peroneal artery: patent

Dorsalis pedis: patent



國泰綜合醫院

醫師 (M.D.)

王榮添、周柏青、林維哲、侯紹敏、柯文欽、張釗監、張嘉修、郭志東、郭書麟、陳玠宇、陳逸忠、黃友君、黃啟宏、黃爽毓、楊宇佳、楊佳穎、葉勳龍、廖智冠、簡韶甫、羅友翎、蘇彥伯、黃晨佑、陳綱隆、勞永健

(依姓氏筆劃順序)

Hybrid room

林秀燕、林玟慧、俞壽如、徐怡婷、徐碧玉、郭文慧、陳建榮、陳盈秀、曾俐綸、鄭雅薰、羅榮卉

(依姓氏筆劃順序)

導管室

江彥鋌、何鎮宇、余正慧、吳慧茹、李振銓、沈憶蓉、林佑容、林玲玲、邱偉豪、張美華、張婷如、梁惠珍、莊鈞廷、許耿瑞、陳青曄、陳亮宇、陳奕廷、陳儀欣、曾雅敏、黃資涓、楊朝宏、劉子平、蔡其峰

(依姓氏筆劃順序)

Date: 2022/01/07 13:30-17:00

- Case 1: Right Coronary Artery Chronic Total Occlusion
Retrograde or antegrade approach under small collaterals
- Case 2: Left main with bifurcation lesions
One stent or two stents?
- Case 3: Severe Aortic Valve Stenosis
With big and tortuous stented abdominal aortic aneurysm
- Case 4: Left ascending artery chronic total occlusion
Should we need image assistance to note the entrance and direction?
- Case 5: Left ascending artery high calcification lesions
What information can IVUS and OCT provide to us?
Rotablation or balloons, that's a question
- Case 6: Left atrial appendage occlusion
For the recurrent cerebral ischemic stroke with atrial fibrillation

Case 1 : Right Coronary Artery Chronic Total Occlusion Retrograde or anterograde approach under small collaterals

Date: 2021/01/07

Operator: Dr. Shih-Chi Liu (劉世奇)

Patient Demographics

Age : 83

Gender : Female

Past Medical History

1. Coronary artery disease, 2VD, LAD 80% stenosis, RCA: total occlusion, Try to recanalized RCA CTO but failure.
2. Paroxysmal atrial fibrillation
3. Old ischemia stroke
4. Hypertension

Risk Factors

Hypertension

Clinical Presentation

Effort angina (CCS class III), Positive stress MPI at inferior/inferolateral wall

Angiographic Findings

Coronary vascular anatomy (2022/10/13)

LM: patent

LAD: middle, discrete up to 80% stenosis



LCX: middle tubular, up to 40% stenosis

RCA: proximal, discrete up to 40% stenosis

RCA: middle, discrete up to 70% stenosis

RCA: distal 100% total occlusion, collateral mainly from LAD

Syntax score : 30 , J-CTO score : 3



Case 2 : Left main with bifurcation lesions One stent or two stents?

Date: 2021/01/07

Operator: Dr. I-Chung Chen (陳逸忠)

Patient Demographics

Age : 74

Gender : Female

Past Medical History

1. CAD post PCI of LCX (DES) and RCA with stenting(DES) and BMS on 2009/09/19
2. CAD post PCI of RCA with RCA on 2018/08/15
3. CAD post PCI of RCA (CTO) with DES 2021/08/10
4. Type 2 DM
5. Hypertension
6. Dyslipidemia

Risk Factors

Diabetes, hypertension, dyslipidemia

Clinical Presentation

Refractory effort angina (CCS class II), Positive stress MPI at anterior and inferolateral wall

Angiographic Findings

Coronary vascular anatomy (2022/11/15)


LM: discrete calcified stenosis up to 80%

LAD: proximal diffuse stenosis, up to 75%

LCX: proximal diffuse stenosis up to 90%

RCA: 99% stenosis post PTCA

Syntax score : 31 EURO score II: 1.61%



Case 3 : Severe Aortic Valve Stenosis With big and tortuous stented abdominal aortic aneurysm

Date: 2021/01/07

Operators: Dr. Jung-Cheng Hsu (許榮城) / Dr. Chi-Hung Huang(黃啓宏)

Patient Demographics

Age : 82

Gender : Male

Past Medical History


1. Severe aortic valve stenosis, degenerative type
2. Abdominal aortic aneurysm post stenting on 2021/05/20
3. Coronary artery disease, post CABG 20 years ago

Clinical Presentation

Effort angina (CCS class III), chest pain and short of breath

Image Findings

1. Echocardiography : Severe AS, mean PG 40mmHg, AVA = 0.88 cm², LVEF 70%, mild to moderate AR, mild MR and TR
2. CT angiography
Annulus (mm): Min 23.9 × Max 29.8 , Mean 25.9 (Perimeter 83.9 mm, Area 529 mm²)
LVOT (mm) : Min 24.2 × Max , Mean 28.6 (Perimeter 82.1 mm, Area 517 mm²) Sinus of Valsalva
diameter (mm): LCC 32.3 , RCC 30.8 , NCC 32.2
Sinus of Valsalva height (mm): LCC 15.7 , RCC 13.0 , NCC 18.4



Case 4 : Left ascending artery chronic total occlusion Should we need image assistance to note the entrance and direction?

Date: 2021/01/07

Operator: Dr. Cheng-Ting Tsai (蔡政廷)

Patient Demographics

Age : 74

Gender : Male

Past Medical History

1. Coronary artery disease (3-vessel-disease) post PCI with BMS for obtuse marginal coronary artery 1 on 2022/10/24.
2. Coronary artery disease (2 Vessel Disease), post PCI with 2 BMS for proximal to distal RCA on 2022/11/21, LAD chronic total occlusion
3. Hypertension
4. Dyslipidemia

Risk Factors

Hypertension, Dyslipidemia

Clinical Presentation

Refractory effort angina (CCS class III), Positive stress MPI at inferior wall

Angiographic Findings

Coronary vascular anatomy (2022/11/21)

LM: patent


LAD: Middle, 100% total occlusion, small collateral from RCA

DB1: tubular stenosis, up to 70%

LCX: middle discrete stenosis, up to 30%

RCA: proximal to distal diffuse stenosis, up to 80%

Syntax score I : 20 , J-CTO score: 3



Case 5 : Left ascending artery high calcification lesions What information can IVUS and OCT provide to us? Rotablation or balloons, that's a question

Date: 2021/01/07

Operator: Dr. Ji-Hung Wang (王志鴻)

Patient Demographics

Age : 78

Gender : Female

Past Medical History

1. Non ST elevated myocardial infarction post percutaneous coronary intervention for right coronary disease
2. End stage renal disease
3. Diabetes mellitus
4. Hypertension

Risk Factors

Hypertension, Dyslipidemia, end-stage renal disease

Clinical Presentation

Dyspnea on exertion (CCS class II)

Angiographic Findings


Coronary vascular anatomy (2022/10/14)

LAD: middle tubular stenosis up to 90%

LX: proximal to middle tubular stenosis up to 50%

RCA: middle tubular stenosis up to 75%

Syntax score : 11, EURO score II: 2.02%



Case 6 : Left atrial appendage occlusion For the recurrent cerebral ischemic stroke with atrial fibrillation

Date: 2021/01/07

Operators: Dr. Wei-Ta Chen (陳威達) / Dr. Shih-Yu Huang (黃爽毓)

Patient Demographics

Age : 66

Gender : Male

Past Medical History

- STEMI history, inferior wall : Coronary artery disease, 3VD, status post POBAS with bare metal stent for m-RCA(2) and POBA for d-RCA on 2020/10/05
- PAOD post PTCA on 2022/10/21
- CAD (2 vessel disease) post PCI on LAD on 2022/10/21
- Heart failure NYHA class 3
- Chronic kidney disease
- Hypertension
- Type 2 Diabetes mellitus
- Dyslipidemia
- Paroxysmal atrial fibrillation Recurrent stroke history


Risk Factors

Hypertension, DM, Chronic kidney disease, heart failure

Clinical Presentation

Short of breath, recurrent ischemic stroke

Image Findings



高雄長庚紀念醫院

醫師 (M.D.)

Masahiko Ochiai	曾建豪	CHIEN-Hao Tseng
方志元 Chih-Yuan Fang	黃民評	Min-Ping Huang
方修御 Hsiu-Yu Fang	楊正旭	Cheng-Hsu Yang
王宗道 Tzung-Dau Wang	葉漢根	Hon-Kan Yip
何明昫 Ming-Yun Ho	鄭又誠	Yu-Cheng Cheng
吳勃銳 Po-Jui Wu	鄭正一	Cheng-I Cheng
吳炯仁 Chiung-Jen Wu	蕭豪毅	Hao-Yi Hsiao
宋沛勳 Pei-Hsun Sung	薛書凱	Shu-Kai Hsueh
李建和 Chien-Ho Lee	鍾文榮	Wen-Jung Chung
林佳濱 Chia-Pin Lin	顧博明	Po-Ming Ku
張韶政 Shavr-Zheng Chong		
陳典佑 Tien-Yu Chen		
陳逸璘 I-Lin Chen		

(依姓氏筆劃順序)

醫事人員 (Nurses & Technicians)

王秀美 Shiu-Mei Wang	蔡估祐	Chi-Hu Tsai
王婉茹 Wan-Ju Wang	謝琦瑜	Chi-Yu Hsieh
王鳳花 Feng-Hua Wang		
李俊豪 Chun-Hao Li		
沈溫雅 Wen-Ya Shen		
阮宣凱 Hsuan-Kai Ruan		
陳妍蓁 Yen-Chen Chen		
黃耀新 Yao-Sin Huang		

(依姓氏筆劃順序)

Date: 2022/01/08 08:30-12:00

-
- Case 1: Carotid artery stenosis
 - Case 2: Right femoral artery calcified long lesion for atherectomy
 - Case 3: Transbrachial Renal Denervation
 - Case 4: Stage PCI to LAD Chronic Total Occlusion
 - Case 5: Left Anterior Descending Artery Chronic Total Occlusion in Coronary Artery Bypass Graft
 - Case 6: STINGRAY for Right Coronary Artery Chronic Total Occlusion

Case 1 : Carotid artery stenosis

Date: 2023/01/08

Operators: Dr. Han-Kon Yip/Dr. Pei-Hsun Sung/Dr. Hao-Yi Hsiao

Patient Demographics

Age : 71

Gender : Male

Past Medical History

1. Diabetes mellitus
2. Hypertension
3. Dyslipidemia
4. 3V-CAD s/p PCI

Risk Factors


None

Clinical Presentation

Bilateral carotid artery stenosis noted during health exam

Angiographic Findings

Rt ICA stenosis s/p PTA with Wallstent 9.0x30 at Rt ICA-CCA (2022/10/19)



Case 2 : Right femoral artery calcified long lesion for atherectomy

Date: 2023/01/08

Operators: Dr. Shu-kai Hsueh/Dr. Wen-Jung Chung

Patient Demographics

Age : 83

Gender : Male


Past Medical History

1. Left common iliac artery stenosis s/p stenting, left common femoral and superficial femoral artery stenosis s/p cutting balloon / DCB x2
2. CAD 2-v-d s/p Cypher DES at LAD in 2008
3. Type 2 diabetes mellitus
4. Hypertension

Clinical Presentation

Right foot resting pain

Angiographic Findings



Case 3 : Transbrachial Renal Denervation

Date: 2023/01/08

Operators: Dr. Tzung-Dau Wang/Dr. Cheng-I Cheng/Dr. Min-Ping Huang

Patient Demographics

Age : 47

Gender : Male

Occupation: Modeling cast worker

Past Medical History

1. Hypertension, under medication: Sevikar 5/40mg 1pc QD, Nebivolol 5mg 1pc HS, Indapamide S.R 1.5mg 1pc QD, spironolactone 25mg 1pc QD, Terazosin 2mg 1pc HS
2. Dyslipidemia; fatty liver
3. Transient ischemia attack history
4. CAD 1-v-d s/p BMS at RCA in 2014
5. Peptic ulcer disease

Clinical Presentation

Resistant hypertension

Angiographic Findings

N/A

Case 4 : Stage PCI to LAD Chronic Total Occlusion

Date: 2023/01/08

Operators: Dr. Masahiko Ochiai/ Dr. Huis-Yu Fang/ Dr. Shavr-Zheng Chong

Patient Demographics

Age : 54

Gender : Male

Past Medical History

1. Angina pectoris with positive MPI study
2. Double vessel CAD (LAD & RCA) s/p PCI with stenting (DESx1) at p-LAD & (DESx1) at PDA in mid Oct 2022
3. Hypertension
4. Hyperlipidemia

Risk Factors

Hypertension, Dyslipidemia

Clinical Presentation

Angina pectoris with positive MPI study (CCS class II)

Angiographic Findings

(2022/10/18)

LM: no stenosis

LAD: proximal to mid LAD had diffuse 80-90% stenosis with heavily calcified distal LAD had CTO and had retrograde collateral from septal branch

LCx: non-dominant vessel; no stenosis

RCA: dominant vessel; Stented PDA (DES 2.25x18mm, 2.5x15mm HPB up to 16atm)



Case 5 : Left Anterior Descending Artery Chronic Total Occlusion in Coronary Artery Bypass Graft

Date: 2023/01/08

Operators: Dr. Chung-Jen Wu / Dr. Chien-Ho Lee

Patient Demographics

Age : 48

Gender : Male

Past Medical History

1. Coronary artery disease, Three-vessel-disease, status post coronary artery bypass graft surgery at 雙和醫院 on 2017/05/31 with occluded graft; s/p PCI/BMSx4 at ostium to distal right coronary artery on 2022/10/24
2. Hypertension
3. Diabetes mellitus, type 2
4. Dyslipidemia

Risk Factors

Hypertension

Diabetes mellitus, type 2

Dyslipidemia

Smoking: 1PPD for 30+ years

Clinical Presentation

Effort angina (CCS class II)

Angiographic Findings

Coronary vascular anatomy (2022/10/21)

LM: Patent

LAD: ostium was totally occluded, Gr.1/3 collaterals from OM and PDA

LCX: distal LCX was totally occluded, OM1 ostium had 75% stenosis

RCA: proximal RCA was totally occluded, mid to distal RCA had diffuse stenosis

LIMA: distal segment had atrophy and was totally occluded

SVG sequentially to OM1, OM3, and PLB was patent



Case 6 : STINGRAY for Right Coronary Artery Chronic Total Occlusion

Date: 2023/01/08

Operators: Dr. Po-Ming Ku/Dr. Cheng- I Cheng/ Dr. Tien-Yu Chen

Patient Demographics

Age : 79

Gender : Male

Past Medical History

1. Triple-vessel coronary artery disease , status post DES to LAD and OM1 on 2021/4/29 , RCA CTO failure on 2021/12/28
2. Hypertension
3. Hyperlipidemia
4. Heart failure with reduced ejection fraction (LVEF:41%)
5. Atrial fibrillation
6. Chronic kidney disease, stage 3 (eGFR:46)

Risk Factors

Dyslipidemia, hypertension

Clinical Presentation

Effort angina (CCS class II)

Angiographic Findings

Coronary vascular anatomy (2021/12/28)

- LM: no significant stenosis
- LAD: no significant ISR at prior d-LAD stent
- LCX: no significant ISR at prior OM1 stent
- RCA: CTO at p-RCA with bridging collateral from conus branch and epicardial collateral channel from atrial branch of LCx



Acknowledgement 誠摯感謝

廠商（依筆畫順序）

Abiomed
 Penumbra Inc.
 Shockwave Medical
 SMT
 上海微創醫療器械（集團）有限公司
 六霖企業有限公司
 友華生技醫藥股份有限公司
 日商朝日英達科技股份有限公司台灣分公司
 台灣百多力有限公司
 台灣百靈佳股格翰股份有限公司
 台灣拜耳股份有限公司
 台灣柏朗公司
 台灣泰爾茂醫療產品股份有限公司
 台灣祥豐醫療器材有限公司
 台灣第一三共股份有限公司
 台灣雅培醫療器材有限公司
 台灣愛德華生命科學股份有限公司
 台灣諾華股份有限公司
 法蘭德生技有限公司
 長拓興業有限公司

美敦力醫療產品股份有限公司
 深圳惠泰醫療器械股份有限公司
 荷商波士頓科技有限公司台灣分公司
 喬昕科技有限公司
 匯悅有限公司
 新加坡商柏盛科技股份有限公司
 新揚行實業
 裕利股份有限公司
 臺灣阿斯特捷利康股份有限公司
 銀鐸實業有限公司
 寬譜醫學科技股份有限公司
 廣泰金屬工業股份有限公司
 輝瑞大藥廠
 興東藥品器材有限公司
 賽諾菲股份有限公司
 鐸牲企業有限公司

協力單位

台大醫院國際會議中心
 台北喜來登大飯店
 宜辰整合行銷有限公司
 琉耀科技股份有限公司

集思國際會議顧問有限公司
 優·視覺溝通
 織谷股份有限公司

SAVE THE DATES

TTT 2024

January 6 Sat. - 7 Sun., 2024

2023 ———— 01.07-08
TAIWAN TRANSCATHETER THERAPEUTICS

大會摸彩

TTT大會超優質雙鳥獎勵方案

DAY1 【早鳥方案】

參加需知：於2023年1月7日週六8:30AM前完成報到，累積課程點數2點即可取得抽獎資格。

早鳥抽獎卷於報到櫃台發放

抽獎時間：2023/01/07 預計1:20PM(摸彩卷需於 1:00PM前投入 就有機會抽中!!)

地點：台大醫院國際會議中心3F

獎品：最新!! iPad 10thGen 64G Wi-Fi版 6台

DAY2 【晚鳥方案】

參加需知：於2023年1月8日週日 1:30PM前完成報到，累積課程點數2點即可取得抽獎資格。

晚鳥抽獎卷於報到櫃台發放及憑識別證於各會議室門口領取

抽獎時間：2023/01/08 預計5:00PM(摸彩卷需於4:40PM前投入就有機會抽中!!)

地點：R201

獎品：最新!! iPad 10thGen 64G Wi-Fi版6台

獎項

iPad 第10代 12名



領取注意事項：

- 憑根聯現場核對資料，直接兌換獎品 (限本人領取)。
- 現場若連絡不到本人，視為棄權。
- TTT大會保留對本活動做中解釋權，及必要時所做之修改、變更。

